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Wound healing is a dynamic process, which is governed by many signaling 
molecules. Nitric oxide (NO) is one such molecule, which regulates the inflammatory 
response, cell proliferation, differentiation and matrix deposition in wound healing. 
Previous in vitro and in vivo studies on the administration of NO donors and 
inhibitors have pointed towards the facilitatory effects of NO in wound healing. 
Similarly the importance of anti-oxidants (GSH) in wound healing has also been 
described. Interaction between NO and GSH is one of the important mechanisms in 
inflammatory processes. In this study we have examined the beneficial effects of 
administering a NO donor S-nitrosoglutathione (GSNO) in wound healing. The 
effects of this agent are compared to S-nitroso-N-acetyl-penicillamine (SNAP), 
which belongs to the same group of compounds and a well-known NO donor. As 
GSNO contains a thiol component i.e glutathione, the effects were compared to 
reduced glutathione. 
Sprague dawley male rats were all subjected to wounding. The two methods of 
wounding in this study were excisional square wounds and incisional-sutured 
wounds. The square wound model was the initial part of the study to examine the 
overall effects of GSNO on wound healing. This was compared to AG, an iNOS 
specific inhibitor. 
In the incisional wound study, the animals were injected with GSNO, SNAP, GSH 
and AG. The drugs were administered daily to respective groups. Six animals (n=6) 
from each group were sacrificed at 3, 5, 7 and 10 days after wounding. GSNO 
 xxi 
improved the rate of wound contraction by 55%. Aminoguanidine did not have any 
noticeable effect on rate of wound healing. Quantitative improvement in wound 
healing was monitored by 1) measuring the material property of the scar in the form 
of load to failure and maximum stiffness 2) collagen content in the scars 3) 
gelatinase activities 4) scar nitrite and nitrate content 5) glutathione concentration 
of the scars. 
 GSNO SNAP GSH AG 
Biomechanical Strength ↑   ↓ 
Collagen content ↑   ↓ 
MMP activity  ↓   
Glutathione  ↓ ↑  
Nitrite and Nitrate ↑ ↑  ↓ 
 
Results obtained from our study have been summarized in the table given above.  ↑ 
indicates increase in the values of the parameters and ↓ indicates significant 
reduction compared to control and  shows no significant difference.  
 
 
Nitrosothiols are thought to represent a circulating reservoir of NO and have 
potential as NO donors, distinct from currently used agents. Because of its wide 
range of effects on wound healing, GSNO has great potential as a therapeutic agent. 
The future applications of GSNO lie in the possibility of increasing GSH levels in 















1.0 The problem statement  
 
The primary function of the skin is to serve as a protective barrier against the 
environment.  Loss of integrity of this barrier results in wounds, which are one of 
the most common pathological conditions. Improper wound healing can cause 
serious concerns in the form of major disability or even death. With increasing age 
of life expectancy, incidence of wounds with various etiologies, have also increased. 
Chronic wounds are a major challenge in health care. Significant part of health care 
expenditure is on wound treatment. Disturbed wound healing may manifest in 
various forms such as ulcers, scars and sores. Excoriations around discharging 
ulcers, repeated infections, malnourishment, severe contractures and physical 
disabilities are the main long-term complications due to delayed or non-healing 
wounds (Prem P. Gogia, 1995). In a study conducted by Ferrell BA (2000) the 
incidence of wounds in the elderly was as follows: 9.12% had pressure injuries, 
37.4% had more than one ulcer and 14.0% had three or more ulcers.  About 30% of 
subjects were at risk for new pressure ulcers. On an average the costs of 
management of pressure ulcer is 1000 US$, full thickness venous ulcer is 2000 US$, 
diabetic foot ulcer 1000 US$ and ischaemic ulcer 2000 US$ 
(http://www.medicaledu.com/outcomes.htm).  The total wound care expenses 
globally runs into billions of dollars. The complications associated with chronic 
wounds are wide such as the cost involved in wound care, psychological and 
physical debilitation.  
 2 
1.1 Current concepts in wound management 
 
Continuous advances made in the study of the wound microenvironment, an ever-
broadening understanding of the pathophysiology of wounds, and improved 
techniques in monitoring the response of healing have led to continuing 
developments in the treatment of chronic wounds.  
The practice of wound management varies from the use of simple gauze dressings to 
complicated skin substitutes. Most commonly adopted strategies in wound 
management are antiseptics and antibiotics in the form of topical ointments to 
prevent contamination. There are various other therapeutic agents, 
pharmacological and biological, available for wound management. However, the 
current challenge is to identify the basic underlying mechanism and appropriate 
therapeutic agent, which enhances wound healing. An ideal wound enhancer must 
be able to prevent contamination, act as a chemotactic to resident host cells, enhance 
reparative tissue deposition and finally prevent the development of a scar. In order 
to enhance wound healing, the agent must also have a facilitatory effect on one or all 
the phases of this reparative process. 
1.1.1 Therapeutic agents in wound healing 
Wound management involves hemostasis, antisepsis, analgesia and 
antimicrobiostasis. The pharmacological and biological agents presently available to 
assist wound management are described below.  
 3 
1.1.1.1 Dressings 
Dressings are now available specifically for individual variety of wounds because of 
the multi-etiologic nature of wounds. They vary from simple cotton gauzes to 
bioactive dressings such as hydrocolloids, moist dressings and hygroscopic agents 
(polymeric agents). The main purpose served by dressings is mainly antisepsis. The 
moist dressings, pressure dressings and cavity dressings are tailor made for venous 
ulcers, cavitating wounds and sores.  
Advanced dressings attempt to specifically maintain a moist wound environment. 
Although they supersede conventional dressings, such as paraffin-impregnated non-
adherent gauze, temporally, they are not always more appropriate and can be more 
expensive. Hydrocolloids, alginates and foams maintain the moist wound 
environment by absorbing exudates, and hydrogels and films donate or maintain 
moisture. Infection-controlling properties of some wound dressings have been 
evaluated recently.  Cadexomer iodine dressing composed of starch lattice into 
which 0.9% w/v iodine is trapped, is highly absorptive facilitating autolytic 
debridement while slow release of iodine maintains levels in the wound bed, where it 
has a broad spectrum of antibacterial activity. Hydrofibre dressing made of 
carboxymethylcellulose, effectively sequesters and retains micro-organisms upon 
exposure to simulated wound fluid, thus providing a passive mechanism for 
reducing the microbial load in wounds and in the surrounding environment.  
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1.1.1.2 Pharmacological agents 
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Table 1.1: Therapeutic agents in wound healing. This table summarizes currently 
available pharmacological agents which support wound healing (Prem P. Gogia, 
1995). 
 
1.1.1.3 Biological agents 
1.1.1.3.1 Growth factors 
The ability study and manipulate the wound milieu has led to the identification and 
separation of a variety of growth factors such as the platelet-derived growth factor, 
epidermal growth factor, transforming growth factor, fibroblast growth factor-β, 
 5 
tumor necrosis factor and interleukin-1. The characterization of the effects of these 
factors and the ability to prepare them in large supply has led to trials of various 
growth factors. The reported effects of growth factor therapy include stimulation of 
cell movement and cell division and increases in matrix synthesis and cell mass, thus 
leading to rapid wound closure. Preparation of the wound bed, choice of growth 
factor appropriate to the stage of healing, and quantity and duration of 
administration are all important considerations in growth factor usage, with the 
presence of protein degrading enzymes in chronic wound fluid constantly 
challenging the survival of these growth factors. 
Currently, the Platelet Derived Growth Factor  (PDGF) is available commercially 
for clinical use. It has been used successfully in the treatment of chronic wounds. 
The major drawbacks in the use of growth factors are: 1) they are expensive 2) 
require stringent storage conditions and 3) require expert handling.   
1.1.1.3.2 Enzymes 
Collagenase has been effectively used in the enzymatic debridement of burn wounds, 
pressure ulcers, necrotic ulcers and infected wounds. Superoxide dismutase 
encapsulated in liposomes has been shown to improve wound healing. The 
drawbacks of this treatment are it is an expensive mode of treatment and is not 
applicable in most of the cases.   
1.1.1.3.3 Gene therapy 
With the technology to introduce and express genes in human somatic cells, 
sustained delivery of wound healing-promoting products is now a real possibility. 
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Vascular endothelial growth factor (VEGF) has increased angiogenic effect in 
wound healing. PDGF is an efficient treatment for chronic diabetic ulcers. Genes 
encoding various growth factors, such as platelet-derived growth factor and 
epidermal growth factor, have been transferred into and induced in wounds, thus 
providing a constant supply of a product that can induce optimal repair. The 
disadvantages are: 1) it is expensive and not extensively used and 2) unlimited 
expression of the gene is undesirable. 
1.1.1.3.4 Miscellaneous 
Hyperbaric oxygen is studied in prevention of necrosis of skin, chronic non-healing 
open wounds and diabetic wound therapy. The advantage is that it limits necrosis in 
ischaemic wound and increases re-epithelialisation. The drawback is that it is 
difficult to administer and accidents such as lung damage are expected.  
Maggots, honey and certain plant extracts such as aloe vera are all reported to 
enhance healing. The potential for maggots to rapidly debride wounds in a nontoxic 
manner has been recognized for centuries. Recent studies directed at larval 
secretions suggest that constituent of the secretions may also act directly as growth 
factors, or alternatively stimulate appropriate cytokine production to facilitate 
wound healing.  Honey has also been used in the treatment of wounds for centuries 
as a result of its efficacy against antibacterial-resistant pathogens as well as its 
ability to debride and promote granulation and epithelialization within wounds. 
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1.1.2 Pitfalls in Current Wound Management 
Current wound management involves providing supportive measures in preventing 
infections, pain and disfigurement. Drugs altering the actual mechanism of 
inflammation, matrix deposition or tissue remodeling are not yet clinically used.  
Recent advances in cellular and molecular biology have greatly expanded our 
understanding of the biologic processes involved in wound repair and tissue 
regeneration and have led to improvements in wound care. As these biologic 
processes are tightly regulated by redox mechanisms we have examined the effects 
of nitric oxide, a highly reactive radical and a key secondary signaling molecule in 
wound healing.  
 
1.2 Quantitative indicators of wound healing 
 
In-order to monitor the prognosis of wound healing, it is important to measure 
certain important parameters. They are a) rate of wound healing, b) collagen 
content of the scar and c) Biomechanical strength.  
1.2.1 Rate of wound contraction 
Clinically, evaluation of wound healing is done by tracking the time taken for the 
complete closure of the wound and the formation 
 of mature scar. This is classically known as the rate of wound healing. The decrease 
in the wound area is technically termed as wound contraction and is the main 
component in wound healing. This also represents the rate of epithelialisation and 
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growth of the granulation tissue which are the key mechanisms regulating wound 
healing.  
1.2.2 Collagen content 
It is the chief indicator of the reparative tissue deposited in the wound environment. 
Collagen deposition begins during the phase of connective tissue deposition and 
granulation formation. The time course of various subtypes of collagen deposition 
has been studied. Briefly, in the early phase of matrix deposition the collagen type 
III is secreted by the fibroblasts, but it slowly matures into type I, which is a thinner 
and mature form of collagen. In an experimental set-up it is important to determine 
the collagen content of the scar as a measure of quality of wound healing. 
1.2.3 Biomechanical strength 
Biomechanical strength is a key factor in determining the final outcome of healing. 
The progressive increase in biomechanical strength of the tissue results from the 
formation and turnover of granulation tissue. Hence the physical quality of the scar 
is measured as the tensile strength. The material properties of the scar are measured 
and the changes in the strength indicate the effects of various treatments on the 






1.3 Physiology of wound healing  
 
Wound healing is a dynamic process requiring the collaborative efforts of many 
different tissues and cell lineages. The behavior of each of the contributing cell types 
during the phases of proliferation, migration, matrix synthesis, and contraction, as 
well as the growth factors and matrix signals present at a wound site, are now 
roughly understood.  Details of how these signals control wound cell activities are 
beginning to emerge and are discussed below.  
A temporary repair is achieved in the form of a clot that plugs the defect, and over 
subsequent days, steps to regenerate the missing parts are initiated. Inflammatory 
cells and then, the fibroblasts and capillaries invade the clot to form a contractile 
granulation tissue that draws the wound margins together. Meanwhile, the cut 
epidermal edges migrate forward to cover the denuded wound surface. 
Fundamental to our understanding of wound-healing biology is, the knowledge of 
the signals that trigger relatively sedentary cell lineages at the wound margin to 
proliferate, to become invasive, and then to lay down new matrix in the wound gap. 
Studies in the last decade have provided a list of the growth factors and matrix 
components that are available to provide these "start" signals, and one of the tasks 
now begun is to relate these factors specifically to the starting and stopping of each 
of the many cell activities by which the wound is healed. Most skin lesions are healed 
rapidly and efficiently within a week or two. However, the end product is neither 
aesthetically nor functionally perfect. Epidermal appendages that have been lost at 
the site of damage do not regenerate, and when the wound has healed there remains 
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a connective tissue scar where the collagen matrix has been poorly reconstituted, in 
dense parallel bundles, unlike the mechanically efficient basket-weave meshwork of 
collagen in unwounded dermis. A major goal of wound-healing biology is to 
understand the mechanisms by which skin is induced to reconstruct the damaged 
parts more appropriately. Wound healing has been clearly divided into three 
overlapping phases (Fig. 1.1), each of which is predominated by a specific 
physiological response. These phases are described in detail below. 
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Fig. 1.1: Schematic representation of phases of wound healing. X-axis represents 
time (days) in log scale and Y-axis represents maximum response. The physiological 
events and the predominant cell type at each phase are depicted in this diagram. 
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1.3.1.1 Coagulation and Inflammation 
Dermal wounds cause leakage of blood from damaged blood vessels. The formation 
of a clot then serves as a temporary shield protecting the denuded wound tissues and 
provides a provisional matrix over and through which cells can migrate during the 
repair process (Fig 1.2A). Importantly, the clot also serves as a reservoir of cytokines 
and growth factors that are released as activated platelets degranulate. The 
activated platelets release a cadre of biologically active substances that promote cell 
migration and growth into the site of injury. Additionally the platelets also release 
their alpha (∝) granules, which contain fibrinogen, fibronectin, thrombospondin 
and von Willebrand factor VIII (Detwiler & Fienman, 1973; Plow E.F, 1986).  
Fibrin and fibronectin act as provisional matrix for the influx of monocytes and 
fibroblasts (Turk, 1976).  Neutrophils are the first leukocytes to enter the wound 
area (Fig. 1.2B).  This early cocktail of growth factors "kick starts" the wound 
closure process. It provides chemotactic cues to recruit circulating inflammatory 
cells to the wound site, initiates the tissue movements of re-epithelialization and 
connective tissue contraction, and stimulates the characteristic wound angiogenic 
response. They ingest the microbial flora, acting as the first line of defense. The 
neutrophils are predominant in the early inflammatory phase and later replaced by 
the monocytes. This marks the end of the early inflammatory phase. They transform 
into tissue macrophages, which in turn ingest the foreign organisms, digest out the 
effete neutrophils and release mediators for the recruitment of the other cells 
(Newman, 1982).  The macrophages release a plethora of growth factors, vasoactive 
mediators, chemotactic factors and enzymes. The chemotactic factors and the 
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growth factors are responsible for the initiation of the granulation tissue (Leibovich, 
1975). Thus the macrophages play an important role in the transition between 
wound inflammation and wound repair. 
1.3.1.2 Cell proliferation and matrix deposition 
1.3.1.2.1 Re-epithelialisation 
Re-epithelialization of a wound begins within hours after injury. In the skin, 
keratinocytes of the stratified epidermal sheet or hair follicle appear to move one 
over the other in a leapfrog fashion (Winter, 1962) (Fig. 1.2C). Alongwith migration, 
epithelial cells undergo marked phenotypic alteration. This metamorphosis includes 
retraction of intracellular tonofilaments, dissolution of most intercellular 
desmosomes and formation of peripheral cytoplasmic actin filaments (Gabbiani, 
1978). One to two days after injury, epithelial cells at the wound margin begin to 
proliferate (Krawczyk, 1971). However, a few days after injury, fibronectin is 
deposited by wound fibroblasts, macrophages, or the migrating epidermal cells 
themselves (Clark, 1982). Wound keratinocytes express functionally active integrin 
receptors for fibronectin in contrast to normal epidermal cells. Thus, wound 
keratinocytes can pave the wound surface with a provisional matrix and express cell 
surface receptors that facilitate their migration across this matrix (Clark, 1982). 
The epidermis dissects through the wound, separating desiccated or otherwise non-
viable tissue from viable tissue (Clark, 1982). Epidermal movement through tissue 
depends on collagenase production by epidermal cells (Woodley, 1982) and 
plasminogen activator. The latter enzyme activates collagenase as well as 
plasminogen (Fig.1.4). The driving forces for epithelial cell movement are 
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chemotactic factors, active contact guidance, loss of nearest neighbor cells, or a 
combination of these processes. As re-epithelialization ensues, basement membrane 
proteins reappear in a very ordered sequence from the margin of the wound inward 
in a zipperlike fashion (Clark, 1982). Epidermal cells differentiate into their normal 
phenotype, once again firmly attaching to the reestablished basement membrane 
through hemidesmosomes and to the underlying neodermis through type VII 
collagen fibrils (Gipson, 1983). 
1.3.1.2.2 Fibroplasia 
Matrix formation begins simultaneously with the formation of granulation tissue 
(Fig. 1.2C). During the dissolution of granulation tissue, the matrix is constantly 
altered, with relatively rapid elimination of fibronectin from the matrix and slow 
accumulation of large fibrinous bundles of type I collagen that provide the residual 
scar with increasing tensile strength. The composition of the granulation tissue 
varies from center to periphery (Bailey, 1975). Extracellular matrix components 
serve several critical functions for effective wound repair. This process includes 
accumulation of macrophages and migration of fibroblasts, deposition of connective 
tissue and angiogenesis. The granular appearance of the tissue is due to the 
numerous newly formed blood vessels. Macrophages, fibroblasts and blood vessels 
move into the wound space as a unit. Fibroplasia and angiogenesis are stimulated by 
the numerous growth factors that are released by platelets and macrophages 
(Gauss-Muller, 1980). Fibroblasts respond to these stimuli by proliferation, 
migration, matrix deposition and wound contraction (Grillo, 1964). The connective 
tissue matrix formed by the fibroblasts provides a substrate on which the 
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macrophages, new blood vessels and fibroblasts themselves migrate into the wound 
area. Thus macrophages, wound fibroblasts and blood vessels are absolutely 
dependent on each other during granulation tissue formation. 
1.3.1.2.3 Neovascularisation  
Angiogenesis is a complex process that depends on an appropriate extracellular 
matrix in the wound bed as well as phenotype alteration, stimulated migration, and 
mitogenic stimulation of endothelial cells. Endothelial cells are phenotypically 
modified during angiogenesis (Ausprunk and Folkman, 1977).  Factors such as 
FGF, TGF-α, TGF-β, TNF-α, angiogenin, angiotropin, vascular endothelial growth 
factor (VEGF), interlieukin-8 (IL-8) and PDGF all promote angiogenesis. The above 
mentioned factors may also induce angiogenesis in vivo by stimulating chemotaxis of 
endothelial cells or by recruiting monocytes or other cells to produce angiogenic 
factors (Ryan, 1977). Proteolytic enzymes released into the connective tissue degrade 
extracellular matrix proteins, including fibronectin. Activated macrophages and 
injured tissue cells release FGF, which stimulate endothelial cells to release 
plasminogen activator and procollagenase. Plasminogen activator converts 
plasminogen to plasmin and procollagenase to active collagenase, and in concert, 
these two proteases digest basement membrane constituents. The fragmentation of 
the basement membrane allows endothelial cells to migrate into the injured site. As 
endothelial cells migrate into the fibrin-fibronectin-rich wound, they form tubes 
that express integrin to facilitate adhesion and migration. The neovasculature first 
deposits its own provisional matrix containing fibronectin and proteoglycans, and 
ultimately forms a true basement membrane (Shelly, 1984; Sten, 1979). In 
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summary, angiogenesis is a complex process depending on at least four interrelated 
phenomena: cell phenotype alteration, chemoattractant-driven migration, mitogenic 
stimulation, and an appropriate extracellular matrix deposition. 
1.3.1.2.4 Matrix deposition 
After a 5-day lag, increased rate of type I collagen synthesis begins, which coincides 
with increased wound-breaking strength (Diegelmann, 1975; Gabbiani 1972). Types 
I and III fibrillar collagen deposition peaks between 7 and 14 days (Clore, 1979). 
Rigid helical collagen macromolecules oriented into fibrillar bundles gradually 
provide the healing tissue with increasing stiffness and tensile strength (Levenson, 
1965). As with types I and III collagen mRNAs, type VI collagen mRNA peaks 
between 1 and 2 weeks after injury (Bruns, 1986). Besides providing structural 
support and strength to the new tissue, collagen affects the activity of the cells 
within the matrix. These effects may be mediated, through activation of the integrin 
collagen receptors (Kurkinen, 1980). The newly deposited matrix rich in collagen 
alters the fibroblasts into myofibroblasts. Perhaps the collagen-rich extracellular 
matrix, which accumulates in mature granulation tissue, reduces the ability of 
wound fibroblasts to produce further collagenous matrix, but promotes the ability 
of these cells to remodel collagen-rich matrix already present.  
1.3.1.3 Matrix Remodeling 
After the initial synthesis and deposition of collagen, myofibroblasts remodel the 
matrix by wound contraction (Fig. 1.2D). Fibroblasts undergo a series of phenotypic 
changes during granulation tissue formation that continually modify their 
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interactions with the extracellular matrix (Gabbiani, 1971). Fibroblasts assume a 
migratory phenotype initially and a synthetic phenotype at a later phase to produce 
collagen (Gabbiani, 1971; Welch, 1990). Subsequently, during the second and third 
week of healing, fibroblasts begin to assume a myofibroblast phenotype 
characterized by large bundles of actin-containing microfilaments disposed along 
the cytoplasmic face of the plasma membrane and the establishment of cell-cell and 
cell-matrix linkages (Welch, 1990). The appearance of the myofibroblasts 
corresponds to the commencement of connective tissue compaction and the 
contraction of the wound. New collagen bundles in turn have the capacity to join 
end-to-end with collagen bundles at the wound edge and to ultimately form covalent 
cross-links among themselves and with the collagen bundles of the adjacent dermis 
(Yamauchi, 2002). These cell-cell, cell-matrix, and matrix-matrix links provide a 
network across the wound whereby the traction of fibroblasts on their pericellular 
matrix can be transmitted across the wound (Singer, 1984). Wound contraction is 
now ascribed to the actin-rich myofibroblasts that, in fact, are the most numerous 
cells in mature granulation tissue and are aligned within the wound along the lines 
of contraction. Collagen condensation is a result from a "collection of collagen 
bundles" executed by fibroblasts as they extend and retract pseudopodia attached to 
collagen fibers (Bell, 1979). The transmission of these traction forces across the in 
vitro collagen matrix depends on two linkage events: fibroblast attachment to the 
collagen matrix through the integrin receptors (Schiro, 1991) and cross-links 
between the individual collagen bundles (Woodley, 1985). Thus, wound contraction 
represents a complex and masterfully orchestrated interaction of cells, extracellular 
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matrix and cytokines. Collagen remodeling during the transition of granulation 
tissue to mature scar is dependent on both continued collagen synthesis and collagen 
catabolism. The degradation of wound collagen is controlled by a variety of 
collagenase enzymes from granulocytes, macrophages, epidermal cells, and 
fibroblasts. These collagenases are specific for particular types of collagens, but 
most cells probably contain two or more different types of these enzymes (Veli-Matti 
Kahari, 1997). Wounds gain only about 20% of their final strength by the third 
week, during which time fibrillar collagen has accumulated rapidly and has been 
remodeled (Levenson, 1965). Thereafter, the rate at which wounds gain tensile 
strength is slow, reflecting a much slower rate of collagen accumulation. Infact, the 
gradual gain in tensile strength depends on collagen remodeling with formation of 
larger collagen bundles and an alteration of intermolecular cross-links (Bailey, 
1975). Even so, wounded tissue fails to attain the same breaking strength as 
uninjured skin. At maximum strength a scar is only 70% as strong as intact skin 
(Levenson, 1965). The early formation of types I, III and V collagen fibrils provides 
nascent tensile strength for the wound. As the matrix matures, the fibronectin and 
hyaluronic acid disappear. The collagen bundles grow in size lending increased 
tensile strength to the wound site and the deposited proteoglycans add resilience to 
the tissue.  
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Fig. 1.2: Phases of wound healing. A) Clot formation – Platelets, fibrin and dead cells form the clot. B) Inflammation – Neutrophils 
migrate into the clot from the surrounding areas initiating inflammatory response C) Re-epithelialisation – Keratinocytes migrate 
into the provisional matrix differentiating the outer scab and the inner neomatrix. D) Matrix remodeling – The collagen deposited 
undergoes remodeling to give the tissue its nascent strength 
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1.4 Factors regulating wound healing 
 
Factors that regulate wound healing are many and are inter-related. Cells either 
secrete growth factors, enzymes or extracellular matrix components which 
coordinate wound healing. The cells and their secreted products in turn affect the 
functioning of other cells through several signaling pathways, thus mutually 
regulating each other’s functions. The factors that regulate wound healing are 
described as follows.  
1.4.1 Growth factors 
Growth factors are polypeptides that are secreted by various cells in response to 
particular stimuli. These factors present in serum and platelet extracts are 
considered to play important roles in wound healing. The effects of growth factors 
are clearly studied in each phase of wound healing as described below. The growth 
factors released from the cells during wound healing and their primary targets are 
listed in Table 1.2. 
1.4.1.1 Coagulation and Inflammation 
Platelet derived growth factor (PDGF)  
In the early phase of wound healing platelets release platelet derived growth factor. 
PDGF is a dimeric glycoprotein with a molecular weight of 30,000, composed of A 
and B chains. It exists as both a heterodimer and a homodimer. The major platelet 
and macrophage isoforms (AB and BB) of PDGF were found to stimulate fibroblasts 
to contract collagen matrix, while the major fibroblast isoform (AA) had no activity 
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(Clark, 1983). It is undetectable in normal human plasma and has a very short half-
life in vivo ( Ross R, 1986; Pierce, 1994). Platelets, macrophages, ECs and vascular 
SMCs have  been shown to secrete PDGF. It is a chemoattractant for neutrophils, 
monocytes, endothelial cells, fibroblasts, smooth muscle cells, and macrophages 
(Bowen-Pope, 1984). PDGF-BB is now available as an adjunct to wound healing. 
The activity of PDGF is thus thought to result from local (i.e., paracrine) effects 
rather than circulating effects. PDGF has mitogenic and chemotactic activity, on the 
target cells. Many cells express receptors for PDGF, including some microvascular 
ECs, dermal fibroblasts, and vascular SMCs (Fig. 1.3). Perhaps tissue macrophages 
release PDGF-BB or -AB approximately 1 week after cutaneous injury, a time when 
myofibroblasts have filled the wound and are linked to each other and to the 
extracellular matrix. This then may be the signal for wound contraction to 
commence (Lepisto, 1995). 
Basic fibroblast growth factor (bFGF) 
Macrophages, smooth muscle cells, vascular ECs, fibroblasts, and some malignant 
tumor cells have all been shown to contain bFGF (Nguyen, 1993). It is a cell-
associated protein that has been localized to the cytoplasm and extracellular matrix. 
It does not have a secretion signal peptide, and its mechanism of release has not 
been clearly elucidated. bFGF can be released from heparan sulfate binding sites on 
the cell surface and in the matrix, or by proteinase degradation of the extracellular 
matrix (Baird, 1986). Basic fibroblast growth factor has been shown to be 
angiogenic in vitro in a number of studies. Although the mechanism of bFGF release 
remains unknown, a unifying hypothesis in all of these cases is that bFGF may be 
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either an effect of, or a reaction to, injury and thus aid in the healing process. bFGF 
has therefore earned the nickname of a "wound hormone." 
1.4.1.2 Cell proliferation and matrix deposition 
Almost all the growth factors so far studied have shown to influence this phase of 
wound healing. Epidermal growth factor (EGF), PDGF and FGF all together 
influence re-epithelialisation. Keratinocyte growth factor (KGF), insulin like growth 
factor (IGF) and transforming growth factor (TGF) all regulate epidermal growth. 
Majority of the growth factors include the EGF family, especially TGF-α 
(Barrandon and Green, 1987), heparin-binding epidermal growth factor (HB-EGF) 
(Higashiyama, 1992) and the FGF family (Werner, 1998). Growth factors may be 
derived from macrophages or dermal parenchymal cells and act on epidermal cells 
through a paracrine pathway (Baird, 1986), TGF-α, and perhaps other growth 
factors, originate from keratinocytes themselves and act directly on the producer 
cell or adjacent epidermal cells in an autocrine or juxtacrine fashion (Dlugosz A. A, 
1994).  
Vascular endothelial growth factor (VEGF) 
VEGF is the key factor that has been studied in angiogenesis of the neomatrix. 
VEGF is a 34 - 42kd homodimeric glycoprotein. The primary target of VEGF is a 
vascular endothelium that possesses two high-affinity tyrosine kinase receptors 
called Fit-1 and Flk-1 (Millauer, 1994). Early studies of the expression patterns of 
VEGF in tumors revealed elevated expression in cells bordering necrotic areas of 
tumors. These observations, in turn, lead to the suggestion that VEGF might be 
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regulated by low local oxygen tensions, that is, hypoxia (Shima, 1995). A number of 
subsequent studies have shown this to be true and have begun to investigate the 
molecular basis of the hypoxic regulation of VEGF. The ability of VEGF to be 
regulated by hypoxia and the knowledge that the wound is a particularly low oxygen 
environment suggest a role for VEGF in wound healing. In addition to its 
angiogenic capacity, VEGF has been shown to alter local protease production 
including plasminogen activator and interstitial collagenase (Pepper, 1991;Unemori 
1992). In addition, VEGF has been shown to induce monocyte migration and 
activation events critical to the successful wound healing response (Clauss, 1990). 
1.4.1.3 Matrix Remodeling 
Transforming growth factor (TGF) 
The effects of TGF-β on extracellular matrix are more complex and more profound 
than those of any other growth factor and are central to its effects on increasing the 
maturation and strength of wounds, (Roberts, 1992; Sporn, 1992; Border, 1994). In 
a dermal site, the target cell is the wound fibroblast, which is first stimulated to 
migrate chemotactically in response to very low concentrations of TGF-β at the 
periphery of the wounded area. This is activated transcriptionally by higher 
concentrations of TGF-β within the wound site. It also regulates the transcription of 
a wide spectrum of matrix proteins including collagen, fibronectin, and 
glycosaminoglycans. Evidence suggests that effects of TGF-β on matrix may be 
mediated through a receptor complex or signaling pathway. They also suggest that 
pathological accumulation of matrix may result not only from excessive production 
of TGF β1, but also from defects in the signaling pathways emanating from matrix 
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that would ordinarily function to terminate or suppress expression of TGF β.  One 
way to assess healing is to measure the strength of an incisional wound. TGF-β 
increases the breaking strength in incisional wounds in rats (Thomas A. Mustoe, 
1987). The effect of TGF β on collagen synthesis is transient and parallels the 
increase in tensile strength. Subsequent collagen cross-linking, on the other hand, is 
not a major determinant of TGF β dependent improvement in repair (Pierce G. F, 
1991). Individual growth factors may regulate different aspects of repair. 
Specifically, with respect to their effects on collagen synthesis, it was shown that 
ulcer wounds treated with TGF β, appeared to bypass the inflammatory phase of 
wound repair (Pierce G. F, 1994). In contrast, PDGF-BB stimulated wound closure 
by augmenting deposition of provisional matrix composed of glycosaminoglycans 
and fibronectin at the edge of new granulation tissue and did not stimulate new 
collagen synthesis until rather late in the repair process. Wounds treated with bFGF 
contained little to no collagen even after complete closure (Pierce G. F, 1991). These 
















Fig. 1.3: Growth factors regulating wound healing. TGF-β1, β2 and β3 are secreted from keratinocytes and macrophages. 
KGF and FGF are secreted by fibroblasts, VEGF by endothelial cells and PDGF by macrophages and fibroblasts. The sources 







factor Source Primary target cells and effect 
EGF Platelets Keratinocyte motogen and mitogen 
TGF-  Macrophages; keratinocytes Keratinocyte motogen and mitogen 
HB-EGF Macrophages Keratinocyte and fibroblast mitogen 
FGFs 




Angiogenic and fibroblast mitogen 
FGF7 





Chemotactic for macrophages, 
fibroblasts; macrophage activation, 
fibroblast mitogen, and matrix 
production 
IGF-1 Plasma; platelets Endothelial cell and fibroblast mitogen 
VEGF Keratinocytes; macrophages Angiogenesis 
TGF- 1 
and - 2 
Platelets; 
macrophages 
Keratinocyte migration; chemotactic for 
macrophages and fibroblasts; fibroblast 
matrix synthesis and remodeling 
TGF- 3 Macrophages Antiscarring 
IL-1  and 
-  Neutrophils 
Early activators of growth factor 
expression in macrophages, 
keratinocytes, and fibroblasts 
TNF-  Neutrophils Similar to the IL-1s 
 
Table 1.2: Growth factors regulating wound healing. The cellular origin and the 










1.4.2 Collagen  
Collagens are a family of glycoproteins containing triple helices, and are main 
components of extracellular matrix. At present, there are 18 collagen types 
designated type I-XVIII according to their chronological order of discovery (Fukai, 
1994). Type I collagen is the major structural component of skin, tendon, bone, and 
many minor structures. Type III collagen is present in skin in association with type 
I. Type VI collagen forms distinctive 100-nm periodic microfibrils intercalated 
between the types I and III collagen of the dermis (Bruns, 1986). Type VII collagen 
forms the anchoring fibrils of epidermal basement membranes (Sakai, 1986). Most 
studies on the collagen content of healing wounds have examined types I and III 
collagens. The function of collagen in the different phases of wound healing and 
regulation of collagen synthesis are described below.  
1.4.2.1 Coagulation and Inflammation 
The inflammatory phase of dermal wound repair is initiated almost immediately 
following tissue injury by either activation of tissue complement or by activation of 
the coagulation cascade. Activation of both of these pathways leads to the 
recruitment of inflammatory cells into the area via the generation of C5a or the 
release of platelet factor, fibrin-degradation fragments. These molecules are 
chemotactic agents in vitro for specific cell types and may play a critical role in the 
early events of wound healing. Fibrillar collagens (types I and III) play a pivotal role 
in the initial stages of wound healing since they are believed to be a key element 
involved in the promotion of platelet aggregation following vascular injury 
(Shoshan, 1981). The binding of platelets to fibrillar collagen in the surrounding 
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connective tissue results in the release of several large glycoproteins such as 
fibronectin and thrombospondin. This collagen-induced aggregation of platelets, 
along with other events in the coagulation cascade, results in the formation of a 
physical plug that provides hemostasis following vascular injury. Platelet ag-
gregation also results in the release of the factors, such as PDGF, fibronectin which 
are chemotactic to inflammatory cells, fibroblasts and smooth muscle cells 
(Gauss-Muller, 1980;Grotendorst, 1985;Seppa 1982). Thus, fibrillar collagen plays a 
crucial role in the early stages of wound healing by such as hemostasis and 
recruitment of connective tissue cells. 
1.4.2.2 Cell proliferation and matrix deposition 
Matrix deposition occurs in an ordered sequence of fibronectin, type III collagen, 
and type I collagen (Kurkinen, 1980).  Type IV collagen, together with other 
components, including a unique heparan sulfate proteoglycan and the glycoprotein 
laminin, makes up both the epidermal and endothelial basement membranes. Type 
VII collagen forms anchoring fibrils that attach the basement membrane to 
underlying connective tissue (Bentz, 1983). Type V collagen in fibrillar form, may 
play a similar role. The migration of fibroblasts into the wounded area and rapid 
vascularization signal the initiation of granulation phase in the wound-healing. This 
phase is generally considered to begin 3-5 days after wounding and persist for 10-12 
days, during which time there is rapid synthesis of type I and III collagen and an 
associated increase in the tensile strength of the wound (Heughan, 1975). In rat 
dermal wounds, significant collagen synthesis begins within 24 hrs of wounding and 
is localized in the area of the panniculus carnosus, the muscle layer underlying the 
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dermis  (Diegelmann, 1975). The collagenous matrix of early granulation tissue 
synthesized by fibroblasts in the wound, in conjunction with non-collagenous 
proteins such as fibronectin and fibrin, provides support for epidermal cell 
migration and proliferation (Clark 1982;Woodley, 1982). Exposure of a granulating 
wound to air results in the formation of a scab (eschar), which is composed 
primarily of dead cells, and dehydrated serum, which attaches itself to the 
underlying granulation tissue. Epithelial cells burrow between the eschar and 
granulation tissue by expressing collagenase and other hydrolases dissolving the 
collagenous matrix in front of them as they move (Harris, 1974). Once wound 
closure is affected, the scab is sloughed off. During wound closure, the provisional 
matrix provided by the early granulation tissue and serum-derived components is 
quite different from the basement membrane. This results in quite different cellular 
behavior characterized by lateral cell movement onto the wound bed and cell pro-
liferation rather than the vertical movement and terminal differentiation char-
acteristic of epithelial cells, when they rest on an intact basement membrane. Once 
cell closure of the epidermis is complete, a basement membrane is rapidly 
synthesized. This signals the end of rapid fibroplasia and the beginning of 
remodeling and maturation of the wound. During the first 3-4 days of wound 
healing, increased amount of type III collagen deposition is seen. Subsequently, a 
rapid increase in the amount of type I collagen was noted (Gay, 1978). The relative 
amounts of other collagen types that participate in the wound healing process are 
low compared with type I and III collagen. Particularly important in the process of 
dermal wound healing is type IV collagen synthesis by epidermal cells and the 
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regeneration of the basement membrane. The synthesis of type V collagen by 
epidermal cells during this migratory phase has also been reported (Stenn, 1979). 
The production of type IV collagen and regeneration of the basement membrane, 
including associated glycoproteins such as laminin, is delayed until the wound is 
covered and the epidermal cells are no longer in a migratory phase. 
1.4.2.3 Matrix Remodeling 
Remodeling and cross-linking of the collagen follows fibroplasia, resulting in 
generation of fibrillar collagen bundles or fibers. These fibers become oriented 
according to lines of stress and provide a slow increase in the tensile strength of the 
healing wound (Heughan, 1975). This remodeling phase in the human ultimately 
results in the formation of a fibrous connective tissue commonly called a scar. The 
role of type I and III collagen in the process of contraction remains to be completely 
elucidated. These matrices provide anchoring points and connecting cables to which 
myofibroblasts bind and attempt to reduce the wound volume through an active 
contraction process (Gabbiani, 1972). Wound contraction is a relatively early event 
in the healing process, which as stated above, involves an interaction between 
myofibroblasts and the extracellular matrix. 
1.4.2.4 Regulation of collagen production 
The factors regulating collagen production during wound healing can be divided 
into those that participate in the early, intermediate, and later stages of the process. 
In the early inflammatory stage of wound repair, platelet factors released during 
clotting may play a key role in regulating collagen synthesis. One such factor is 
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PDGF (Knighton, 1982). This factor could promote collagen synthesis by recruiting 
connective tissue cells into the wound via its chemotactic activity (Seppa, 1982) and 
causing them to proliferate via its mitogenic effect (Rutherford and Ross, 1976). 
Another platelet factor, TGF-β, has been reported to enhance the rate of connective 
tissue deposition (Sporn 1982). Large-scale proliferative response of fibroblasts and 
associated deposition of connective tissue in the wound bed does not begin until the 
acute inflammatory phase begins to subside at 3-5 days (Clore J. N, 1979). The 
released growth factors promote collagen synthesis by increasing the number of 
connective tissue cells in the wound site. Several other lines of evidence implicate 
macrophage in the control of collagen deposition in wounds. Thus, it now appears 
that macrophages play an important role in fibroplasia and associated collagen 
deposition during the intermediate stages of wound healing by secreting a host of 
factors that enhance fibroblast proliferation. They promote these cells to synthesize 
and secrete extracellular matrix proteins. In addition to the requirements for 
chemoattractants and mitogens to promote new collagen synthesis, some 
investigators have hypothesized that reduced oxygen tension in the wound, due to 
the high metabolic activity of cells in the wound bed, also plays an important role in 
the wound healing process. These investigators suggest that reduced oxygen tension 
results in local hypoxia and lactate production, which in turn promotes new collagen 
synthesis (Levene and Bates, 1976). On the contrary, re-epithelialization of the 
wound is negatively affected by reduced oxygen and positively influenced by 
increased oxygen levels (Winter, 1978). Thus, while there is circumstantial evidence 
that oxygen tension may play a role in the regulation of new collagen synthesis in 
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wounds, the mechanisms by which this effect may be regulated remains to be 
determined. Another regulatory event of collagen production in the wound healing, 
particularly at the later stages of the process, is the catabolism of newly synthesized 
collagen. The rate of collagen degradation changes as wound healing proceeds, 
starting out at a relatively slow rate during the early stages of the process and 
increasing as wound maturation occurs (Zeitz, 1978). 
1.4.3 Enzymes  
Wound healing is a dynamic reparative process involving debridement, 
inflammation and matrix deposition. All these metabolic processes require efficient 
expression and activity of enzymes. These include matrix metalloproteinases 
(MMPs) and enzymes involved in the free radical metabolism. The following section 
provides a detailed description of these enzymes and their role in wound healing.   
1.4.3.1 Matrix-metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases 
collectively capable of degrading essentially all components of extracellular matrix. 
The members of this family are divided into four groups namely collagenases, 
gelatinases, stromelysins and membrane type MMPs (MT MMP) according to their 
substrate type specificity and primary structure. Controlled breakdown of ECM by 
MMPs plays an important role in detachment and migration of cells as well as in 
tissue remodeling. MMPs play an important pathogenic role in excessive breakdown 
of connective tissue components e.g., arthritis, ulcers, dermal photoageing, 
periodontitis, tumor cell invasion etc. In skin, several different types of cells are 
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capable of producing MMPs: keratinocytes, fibroblasts, macrophages, endothelial 
cells, mast cells, eosinophils and neutrophils. These enzymes are primary mediators 
of collagen turnover and are secreted as zymogens that can be activated by certain 
other proteases such as plasmin (Werb, 1989). This activation of the collagenase, as 
well as inhibition of its enzymatic activity by protease inhibitors such as α--
macroglobulin, have been proposed to play critical roles in the regulation of 
expression of collagenolytic activity in vivo (Werb, 1989; Diegelmann, 1990). The 
activities of these enzymes are controlled by various inhibitor counterparts called 
tissue inhibitor of metalloproteinases (TIMP), which play an important role during 
development (Overall, 1991) and wound repair. Cytokines such as TGF β, PDGF, 
and IL-1 and the extracellular matrix itself may play an important role in the 
modulation of collagenase and TIMP expression in vivo (Werb, 1989; Circolo, 1991; 
Sporn and Roberts, 1992).  With certain exceptions the MMPs are not constitutively 
expressed in the skin but are induced temporarily in response to exogenous signals 
such as the cytokines or growth factors, cell- matrix interactions etc. The primary 
MMP’s involved in wound healing are described in the following section. 
1.4.3.1.1  72-kDa gelatinase (MMP2) 
Gelatinase A is unique in that it is constitutively expressed by many cells, has a 
ubiquitous tissue distribution and has a cell surface mode of activation that differs 
from the other MMPs.  Structurally this enzyme is similar to the rest of the MMPs. 
In addition to the shared domains, both gelatinases (A and B) have an additional 
fibronectin-like gelatin binding domain that provides substrate specificity of these 
enzymes (Cao, 1995).  
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 1.4.3.1.1.1 Regulation of Gelatinase A activity 
 
The activity of Gelatinase A is controlled by many regulatory mechanisms. They are 
as described as follows 
a) Transcriptional regulation of Gelatinase A expression 
Gelatinase A is constitutively expressed in many cells. The gelatinase promoter is 
characterized by the absence of AP-1, PEA-3 which is present in the other protease 
promoter regions. This promoter site has a unique TATA box as well as an 
enhancer element at –223 to –422 nucleotides.  The distinctive features of this 
enzyme promoter include SP-1 sequence at 120bp from the start site and adenovirus 
E1A repressor element. As Gelatinase A is constitutively expressed and not well 
regulated it has led to the understanding that it acts as a housekeeping enzyme.  
b) Post-transcriptional regulation of Gelatinase A expression 
TGF β-1 supresses the overall MMP activity but enhances the levels of Gelatinase A 
secreted by human fibroblasts and rat osteoblasts (Overall, 1991). It is shown that 
TGF β increases the stability of the gelatinase  mRNA. 
c) Regulation of the activity of Gelatinase A by TIMP’s  
Progelatinase A is usually found complexed with TIMP-2. It binds to the C-terminal 
domain of progelatinase-A and regulates its activity. Recent studies show that 
TIMP-2 may mediate the cell surface activation of progelatinase A by binding to a 
MT1-MMP containing complex on the cell surface. Thus TIMP-2 facilitates the cell-
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surface mediated activation of the progelatinase-A and also the inhibition of the 
active enzyme.  
d) Regulation of activation of Gelatinase A proenzyme  
In-vitro activation by APMA and chaotropic agents: The MMPs are latent because 
their unpaired cysteine residue in the pro-domain and the Zn atom at the active site 
are well co-ordinated. Upon the dissociation of the cys-Zn interaction, progelatinase-
A undergoes an autolytic cleavage. This results in a removal a 8-kDa peptide by 
hydrolysis and activation of the proenzyme. 
e) Regulation of Gelatinase A activity by MT1-MMP and α5β3  
MT-MMP acts as a receptor for TIMP-2. The MT-MMP-TIMP complex can bind to 
progelatinase-A and form a trimeric complex. Formation of this complex leads to 
the activation of the progelatinase A. Binding, localization and activation of the 
progelatinase A on the cell surface depends on the cooperative interaction of all the 
proteins. Interestingly in some tumor cell lines it has been shown that α5β3 
enhances the surface binding of the progelatinase A. It has also been shown that 
thrombin and urokinase facilitate the cell surface activation of progelatinase A. This 
suggests that multiple cellular control mechanisms may be evoked to control the 





1.4.3.1.1.2 Functions of Gelatinase A in cellular processes 
a) Regulation of Cell proliferation and differentiation  
In a mesangial cell model Turck et al (1996) have demonstrated that the expression 
of Gelatinase A coincides with the phenotypic transformation of the cells into those 
of the inflammatory stage. The inhibition of transcription of the Progelatinase A 
protein results in the failure of the cells to change into those of the inflammatory 
phase.  Gelatinase A also cleaves fibronectin which is one of the key extracellular 
matrix components along with collagen (Stetler-stevenson, 1989).  
b) Modulation of cell adhesion and migration  
Recent studies in melanoma and breast cancer cells have shown that gelatinase A 
decreases the adhesion of the cells to their substrates and increases their migration. 
Studies’ involving the cleavage of the Ln-5γ2 subunit of Laminin-1 by gelatinase A 
exposes the putative cryptic pro-migratory site that triggers cell motility but not cell 
adhesion (Calof, 1994).  During cell migration as in tumor cell invasion, the 
degraded protein products serve as stimulus for cell movement. While it is 
established that proteolysis is required for tumor invasion, certain studies suggest 
that excessive proteolysis may inhibit cell-matrix interactions and matrix signals 
that are required for migration and invasion. 
1.4.3.1.2  92-kDa gelatinase (MMP9) 
This enzyme is homologous to the gelatinase A and degrades the type IV collagen 
and gelatins. The protein consists of several structural domains. Both the gelatinases 
have an additional fibronectin like domain. The protein is maintained in the inactive 
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state by a cysteine switch mechanism. When the interaction between the zinc and 
cysteine is disrupted the enzyme is activated.  The activation depends on the state of 
the enzyme as it is mostly linked with TIMP-1. Gelatinase activation is also brought 
about by cathepsin G, trypsin, α chymotrypsin and stromelysin. The activation of 
the progelatinase-B TIMP-1 complex by APMA or trypsin results in poorly active 
Gelatinase B whereas activation by other MMPs results in a higher activity 
(Montogomery, 1993). Gelatinase B is widely thought of as a type IV collagenase as 
it cleaves native type IV collagen molecules. It also cleaves aggrecan, a cartilage 
proteoglycan.  Other non-ECM substrates of Gelatinase B are Myelin basic protein, 
galactoside-binding proteins etc.  
 
1.4.3.1.2.1 Regulation of Gelatinase B activity 
a) Regulation by growth factors and cytokines  
Most of the growth factors have been found to increase the activity of Gelatinase B, 
for e.g., TGF-β, EGF, bFGF, interleukins, TNF-α and IFN-γ. A number of proteins 
such as the granulocyte chemotactic protein and leukocyte inhibitory protein also 
induce the expression of this enzyme (Mertz, 1994). 
b)  Regulation by Cell-Cell and Cell-matrix interaction 
Gelatinase expression is also controlled by cell adhesion molecules, ECM and agents 
that change the shape of cells. Laminin peptide SIKVIV induces gelatinase 
expression in human monocytes. Cell-cell contact also up-regulates gelatinase B 
activity (Huhtala, 1995). Certain co-culture experiments have proven that the cell-
cell contact is important for the expression of gelatinase B.  
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 1.4.3.1.2.2 Functions of Gelatinase B in cellular processes 
 
a) Tissue injury, inflammation and wound healing 
Most of the inflammatory cells such as the neutrophils, lymphocytes, eosinophils, 
mast cells and macrophages express gelatinase B (Leppert, 1995). The degradation 
of the subendothelial basement membrane during the process of inflammation is 
brought about by gelatinase B. Increased MMP-9 is found in infarcted heart, acute 
respiratory distress syndrome and burns. MMP-9 appears during the early phases 
of burns, whereas MMP-2 is expressed at a later stage along with stromelysin 
(Young, 1994). Gelatinase B is expressed in the early inflammatory phase of tissue 
repair whereas Gelatinase A appears at a later stage. 
b) Implantation  
The embryonic trophoblast invades the uterine epithelium by the secretion of 
gelatinase B. It is also expressed in the perital endoderm that may play an important 
role in the expansion of Reichert’s membrane (Behrendtsen, 1992).  
c) Bone development 
The degradation of cartilage and the resorption of bone are carried out by 
osteoclasts (Okada, 1995). These cells express high levels of gelatinase B during the 
bone remodeling and initial migration from perichondrium into the cartilaginous 
bone model before the initiation of ossification process.  
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1.4.3.1.3 Gelatinases as applied to wound healing 
MMP 2 and 9 are thought to play a key role in the final degradation of fibrillar 
collagens after initial cleavage by collagenases. MMP 2 cleaves native type I collagen 
to N-terminal ¾ and C-terminal ¼ fragments identical to those generated by 
collagenases. In addition, MMP 9 has been shown to cleave type I, II and V 
collagens in the N-terminal non-helical telopeptide. Therefore it is possible that 
MMP 2 and MMP 9 play a more important role in the remodeling of collagenous 
ECM than has been previously thought. In a murine model the MMPs have been 
localized to the basal cells of the hyperproliferative epithelium (Liotta, 1979). The 
Gelatinase B is absent in the non-wounded epidermis. Gelatinase A is released later 
during the repair i.e. in the granulation tissue formation.  Maximum activity of 72 
kDa Gelatinase is seen between day 5-7, post- wounding (Akiko, 1997). Thereafter 
the activity decreases and by day 13 it reaches that of the normal skin. MT1-MMP is 
co-localized with 72kDa Gelatinase. It is a physiological activator of the 72kDa 
Gelatinase. This suggests that there is a high level of gelatinolytic activity in the 
provisional matrix. TIMP-1 which binds to most activated MMPs is expressed with 
similar kinetics as collagenase, 92kDa Gelatinase and stromelysins. TIMP 2 that is 
secreted as a complex with 72kDa progelatinase shows a constant level during entire 
time period. The various MMP’s released and their actions are briefly summarized 





 Fig. 1.4: Enzymes acting during re-epithelialization. Matrix Proteases such as matrix metalloproteinase (MMP), urokinase type
plasminogen activator (u-PA) and  PA are secreted into the fibrin clot. This promotes re-epithelialization and fibroblast migration
into the matrix (Adam J. Singer, 1999) (Permitted by Massachusetts Medical Society – Appendix B). 
 40 
1.4.3.2 Enzymes in free radical metabolism 
Cells possess various mechanisms to protect themselves from the free radical-
mediated damage defined as scavengers. And among these, some enzymes have the 
role of anti-oxidants.  A brief summary of the role of these enzymes in the free 
radical metabolism is given in Table 1.3. 
 
Enzymes Function 
Glutathione peroxidase Reduction of hydrogen peroxide 
H2O2 + 2GSH →  2H2O + GSSG 
Glutathione-S-Transferase Reduction of fatty acid hydroperoxide 
Peroxidase Reduction of fatty acid hydroperoxide and 
hydrogen peroxide 
H2O2 + AH2 →  2H2O + A 
Catalase Reduction of hydrogen peroxide 
2H2O2 → 2H2O + O2 
 
 
Table 1.3: Decomposition of hydro peroxides and hydrogen peroxides by enzymes. 
The enzymes that catalyze the peroxidation reactions are shown in this table. 
 
 
1.4.4 Free radicals 
Free radicals are chemical species, which contain one or more unpaired electrons 
and are capable of independent existence. In biological systems, these reactive 
radicals tend to combine with cellular and extracellular components. Lipids, 
proteins, nucleic acids, sugars and metabolic intermediates are the targets of these 
radicals. The consequences are either in the form of chromosomal aberrations, 
cytotoxicity, carcinogenesis, cellular degeneration and apoptosis.  
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Glutathione, a free radical plays a unique role in the cellular defense against active 
oxygen species and reactive intermediates. GSH functions both as a reductant in the 
metabolism of hydrogen peroxide and organic hydroperoxides and as a nucleophile, 
which can conjugate electrophilic molecules. During glutathione peroxidase-
catalysed metabolism of hydroperoxides, GSH serves as an electron donor, and the 
glutathione disulfide (GSSG) formed in the reaction is subsequently reduced back to 
GSH by glutathione reductase, at the expense of NADPH. Under conditions of 
oxidative stress, when the cell must cope with large amounts of H2O2 or organic 
hydroperoxides, the rate of glutathione oxidation exceeds the slower rate of GSSG 
reduction by glutathione reductase, and GSSG accumulates. To avoid the 
detrimental effects of increased intracellular levels of GSSG (e.g., formation of 
mixed disulfides with protein thiols), the cell excretes GSSG, which can lead to 






































g. 1.5: Formation and metabolism of active oxygen species.  Metal ions (Mn ) and 
e enzymes catalyzing the metabolism of oxygen species are shown in this figure. 
otein thiol formation is also represented (prot-SH). 
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1.4.4.1   Free radicals in skin 
Wound healing involves the initiation of events, which involve the release of reactive 
oxygen species (ROS) as part of their defense mechanism. In the inflammatory 
phase of wound healing numerous PMN and macrophages invade the injured area 
(Trenam, 1992). Once activated, they produce large quantities of reactive oxygen 
species (ROS) as part of the defense mechanism (Darr D, 1994). Although this 
process is beneficial, increased levels of ROS can inhibit cell migration and 
proliferation and can even cause severe tissue damage. Therefore cells adopt 
strategies to detoxify these molecules. The PMN and macrophages destroy the 
contaminating bacteria and debride the dead tissue by phagocytosis and the release 
of ROS (Kanegasaki S, 1992).  If the wound contamination is limited, the 
neutrophils cease to infiltrate and the reparative phase begins. The production of 
ROS in the inflammatory response is termed respiratory burst (Clark R. A. F, 
1990). Neutrophils and tissue macrophages produce ROS by cytochrome-b 
dependent oxidase to reduce molecular oxygen to superoxide anions. Simultaneously 
the other cells, such as the fibroblasts are stimulated to release ROS by the 
interleukin-1 and tumor necrosis factor α (Epstein J. H, 1977). Excess of free 
radicals are adverse for the normal functioning of cells. Therefore it is important for 
the cells to detoxify the excess ROS. The main mechanisms through which the cell 
can detoxify the ROS are 1) small antioxidant molecules like ascorbate, poly-
unsaturated fatty acids or sugars and 2) enzymes such as superoxide dismutase, 
catalases and various peroxidases (Schroder, 1995). They have the tendency to react 
more or less rapidly with other free radicals or non-radicals by donating or 
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accepting an electron and therefore the process proceeds as a chain reaction. When 
generated these free radicals tend to combine with several cellular and extracellular 
components. Unsaturated lipids, proteins, nucleic acids, sugars, metabolic 
intermediates etc., react with free radicals. The biological consequences of these 
reactions include mutations, chromosomal aberrations, cytotoxicity, carcinogenesis, 
cellular degeneration and death. Oxygen free radicals are known to be the 
mediators of tissue damage during catabolic states (Griffits C. E, 1991). The body 
utilizes antioxidant substances made endogenously or provided in the diet as free 
radical scavengers, to attenuate oxidant-mediated peroxidation of lipid membranes 
and disruption of cell proteins in extracellular fluid and in tissues (Picardo, 1992). 
Several dietary nutrients, including zinc, selenium, vitamins A, C, and E, and 
glutamine, appear to function as antioxidants or are involved directly or indirectly 
in the generation of critical antioxidants such as glutathione (GSH) (Picardo, 1990). 
Maintenance of GSH concentrations in tissues and in the circulation, serves to 
inhibit lipid peroxidation of cell membranes. Thus, GSH (a glutamate-cysteine-
glycine tripeptide) is a key antioxidant in the body (Picardo, 1990). The metabolism 
of nutrient antioxidants is interrelated. For example, tissue protection by ascorbate 
and glutathione against microsomal lipid peroxidation is dependent on vitamin E. 
Enzymes involved in GSH generation, such as glutathione peroxidase, are 
dependent on adequate supplies of the trace metal cofactors such as zinc and 
selenium. Several studies indicate beneficial effects on tissue GSH production with 
GSH inhibitor administration in animal models of tissue injury and inflammation. 
Emerging clinical trials suggest that administration of single antioxidants, such as 
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vitamins C and E, or antioxidant nutrient "cocktails" reduces indices of oxidant 
damage and tissue injury in selected groups of catabolic patients, including those 
with pancreatitis or burn injury and after operation (Wang Y, 1995). In addition, 
several studies suggest that beneficial clinical effects occur with administration of 
enteral diets enriched in combinations of antioxidant and "immunomodulating" 
nutrients, including arginine, glutamine, fish oil, selenium, zinc, and vitamin C 
(Bissett, 1990). Although there is as yet little evidence for interactions between 
growth factor hormones and antioxidant nutrient action pathways, it is likely that 
diminution of oxidative tissue damage by certain nutrients serves to facilitate 
growth factor-induced tissue growth and repair.  
1.4.4.1.1 Anti-oxidant systems 
a) Primary defense systems 
Superoxide dismutase is an enzyme that catalyses the dismutation of O2- into oxygen 
and water.  
O2- + O2-+2H+             H2O2 + O2    → (1) 
2H2O2      2H2O + O2   →      (2) 
Reaction (1) is catalysed by superoxide dismutase and (2) by catalase and 
glutathione peroxidase.  
b) Secondary defense systems 
One of the most secondary defense systems is α tocopherol. It quenches and reacts 
with almost all the radicals known. It is reduced by ascorbic acid and glutathione 
 46 
and this in-turn maintains the antioxidant status. Ubiquinone is another reducing 
agent found in the mitochondria and cellular membranes of mammalian cells. 














Scald size Karola Vorauer (2002) 
Vit C Keratinocytes ↑ collagen Steven T Boyce (2002) 






Ascorbic acid Human wounds ↑strength Vaxman.F (1996) 
EGF + Nafomostat Full thickness burns (rat) ↑ S.O.D 
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Table 1.4: Summary of previous studies on the administration of free radical 
scavengers/anti-oxidants in wound healing. SOD - superoxide dismutase, VitC – 




1.4.5 Metal Ions 
Metal ions are the regulating factors of the activity of the enzymes. The main ions 
that are of importance are Zinc ions, which regulate the activity of 
metalloproteinases and copper, selenium and ferric ions that regulate enzymes in 
the Fenton pathway. 
 
1.5 Biology of Nitric oxide 
Nitric oxide was initially identified as a blood vessel relaxing factor derived from 
endothelia (Palmer, 1988) and has been shown to possess a variety of physiological 
and pathophysiological activities in living systems. In the central and peripheral 
nervous systems, it appears to be an inter and intra cellular messenger molecule, 
which functions as a neurotransmitter (Nathan C, 1992). In the vascular system, this 
molecule plays an important role in maintaining the tone of the vessel (Palmer, 
1988). In the immune system, all mononuclear leukocytes and neutrophils have the 
capacity to synthesize NO upon stimulation. These stimulated cells in turn perform 
the cytotoxic and inflammatory functions (Nathan C, 1992). NO also serves as a 
signaling molecule between the immune system and other organ systems by 
transmitting cytokine signals to the regulatory machinery of a variety of cells 
(Jeanette R Hill, 1996; Schneemann M, 1993). 
1.5.1 Nitric oxide biosynthesis: The Arginine NOS pathway 
The biosynthesis of NO is mediated by Nitric Oxide Synthase (NOS), an NADPH 
dependent enzyme that catalyses the oxidation of L- arginine with molecular oxygen 
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to form NO and L-citrulline (Kwon, 1990).  NOS is a complex enzyme involving 
several tightly bound redox co-factors (NADPH, FAD, FMN and pterin) that are 
clearly organized into distinct domains (Marletta, 1998). There is a structural 
similarity between the NOS and NADPH cytochrome P- 450 reductase since it 
contains a heme moiety and the C- terminal part of the protein shows sequence 
homology to cytochrome P-450 reductase (Bredt, 1991). Three isoforms of NOS are 
now distinguished by cloning of their genomic and complementary DNA (Bredt, 
1991). Activities of two of these are dependent on elevated intracellular Ca 2+ and 
extrinsic calmodulin. These are constitutively expressed (cNOS) (Fig 1.6). One is 
restricted to endothelial cells (endothelial NOS, eNOS) while another is expressed in 
specific neurons (neural NOS, nNOS) of the central and peripheral nervous system 
and in skeletal muscles (Nakane M, 1991). These two isoforms of NOS oxidize L-
Arginine to form small amounts of NO (n moles) and citrulline in response to signals 
that elevate intracellular Ca 2+. The third isoform, the Inducible NOS (iNOS) is 
independent of the elevated intracellular Ca 2+ (Fostermann U, 1994) (Fig 1.6). This 
isoform is not expressed under normal conditions, but can be induced in many types 
of cells by inflammatory cytokines and bacterial lipopolysaccharide (LPS). In the 
process of inflammation and immune responses, cytokines and bacterial products 
stimulate the expression of iNOS in a wide variety of cells that converts L-arginine 
to form high levels of NO, resulting in a diversity of beneficial and detrimental 
consequences (Petros, 1994). All of the NOS isoforms require NADPH and 
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Fig. 1.6: Metabolism of L-Arginine by NOS isoenzymes. A) Constitutive isoenzyme 
(cNOS) metabolizes L-Arginine to NO and L-citrulline. Calmodulin activation by 
calcium is important. B) Inducible isoenzyme (iNOS) metabolizes L-Arginine to NO 
and L-citrulline. This enzyme is induced by bacterial endotoxins and 
lipopolysaccharide. NADPH is nicotinamide adenine di nucleotide phosphate in the 
reduced form. O2- is the superoxide anion. 
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1.5.2 Mechanism of action of NO in wound healing 
The initial finding that, in cases of protein calorie malnutrition arginine could 
enhance wound healing sparked interest in identification of NO as a key molecule in 
the process of wound healing. Intravenous alimentation enabled/enhanced 
appropriate wound healing (Adrian Barbul, 1985). The cellular mechanisms 
affected by NO are the oxidation of Sulfhydryl groups, formation of complexes with 
amines in organic solvents and in the activity of metal containing proteins. The vital 
role either as a physiological messenger or as a cytotoxic agent played by NO 
depends on other free radicals present and it’s concentration. NO reacts with 
molecular oxygen or superoxide to produce reactive Nitrogen Oxide species 
(RNOS), which mediate certain important reactions (Nathan, 1992). By the virtue of 
its high reactivity and simple chemical structure NO is implicated in promotion of 
wound healing. Enough evidences have shown biphasic effect of NO on wound 
healing. Increase in NO concentration increased collagen syntheses in some studies 
while others have shown inhibition of protein synthesis and in-turn collagen. 
Different cells such as macrophages, neutrophils, lymphocytes, fibroblasts and 
keratinocytes involved in wound healing liberate NO. This radical regulates certain 
key pathways in their performance as important metabolic components in wound 
healing. 
1.5.2.1 Coagulation and Inflammation 
The initial platelet rich coagulation phase is paralleled by increase in NO 
concentration. Platelet aggregation is inhibited following administration of NO 
donors. Certain other studies have indicated that NO is a primary mediator in 
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platelet neutrophil interactions (Aki Hirayama, 1999). Thus various opinions and 
observations exist on the role of NO in platelet function. PDGF mediated vascular 
smooth cell migration, an important event in wound healing is regulated by NO 
(Asha Jacob, 2002). Neutrophils when stimulated produce increasing amounts of 
NO (Nathan, 1992). These activated neutrophils release many cytokines such as IL-8 
and TGF- β which are important mediators of wound healing. The release of these 
cytokines is known to be regulated by NO (Vodovotz, 1994). Certain other cytokines 
such as, monocyte attracting chemotactic agents released by marginal keratinocytes 
are known to be downregulated by NO (Christian Wetzler, 2000). NO inhibits the 
NFκB activation, a key initiating event in inflammatory process (Ann F. Haas, 
1998). This in turn results in lowered inflammatory response. As NO plays distinct 
roles in various cells and in different pathways, the exact role of NO in coagulation 
and inflammation which is the initial event in wound healing has yet to be clearly 
understood. 
1.5.2.2 Cell proliferation and Matrix deposition 
In the second phase of wound healing the ongoing physiological responses are 
fibroplasia, angiogenesis, re-epithelisation and the initiation of extracellular matrix 
synthesis (Clark R.A.F, 1982). The predominant process during this phase is re-
epithelisation and angiogenesis. The highly proliferating epithelial tongue covers the 
wounded area. NO represents a potent mediator for epithelial regeneration and is 
independent of the presence of other protein type mitogens (Heck D. E., 1992). 
Wounds fail to epithelialize in the event of NO inhibition inspite of the presence of 
optimum concentration of keratinocyte growth factor. The inhibition of 
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keratinocyte proliferation of UV damaged skin following administration of NOS 
inhibitor supports the fact that NO initiates the keratinocyte proliferation. In low 
concentration, NO promotes keratinocyte proliferation and in higher concentration 
mediates differentiation. Thus NO accelerates wound closure and offers an effective 
signaling pathway in re-epithelization. There has been evidence of co-expression of 
iNOS and GTP-CH1, which are important in melanogenesis and keratinocyte 
differentiation. The endothelium derived NO maintains the surface expression of 
certain adhesion molecules in endothelial cells that are necessary for cell migration 
(Wei. X. Q., 1995). Angiogenesis occurs due to a switch of the endothelial cells from 
their stationary phase to a replicative phase (Justus Benrath, 1995). NO regulates 
angiogenesis which plays a central role in the revascularisation of the scar tissue. 
Macrophages play an important role in angiogenesis which is regulated by NO 
(Leibovich, 1975). VEGF secreted by keratinocytes is a potent inducer of 
angiogenesis. This in-turn is under the influence of NO produced endogenously. The 
action of NO induction of VEGF mRNA is on the transcriptional level in the 
keratinocytes. The response of NO on VEGF expression is primarily on gene 
activation. Inhibition of inducible nitric oxide-synthase (iNOS) enzymatic activity 
during cutaneous wound repair leads to severely impaired tissue regeneration. In 
vitro studies confirmed a regulatory role of NO for keratinocyte-derived chemokine 
expression, as NO attenuated IL-1β and TNF-α induced MCP-1 mRNA expression, 
whereas NO augmented IL-1β induced IL-8 (functional human homologue to 
murine MIP-2) mRNA expression in the human keratinocyte cell line HaCaT.  In 
the wound environment certain cytokines such as IL and IFN act synergistically 
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with NO in induction of VEGF mRNA (Stefan Frank, 1999). Recently keratinocyte 
growth factor is found to be a powerful mitogen for keratinocytes. It has a 
synergistic action in inducing VEGF mRNA in keratinocytes. The cumulative effect 
of exogenous KGF and NO is increased induction of VEGF mRNA (Frank S, 1999). 
The effect of NO on VEGF expression is dependent on the type of the cell it acts. For 
e.g. in the smooth muscle cells VEGF expression is decreased by  NO (Pipili-Synetos 
E, 1994). Thus one of the key processes regulated by NO is the regulation of growth 
factor and cytokine-triggered processes in wound healing. Thus the presence of 
constitutive concentration of NO is important in the regulation of angiogenesis. As 
NO is a very well known vasodilator the vascular permeability in the vicinity of 
wound is under the direct influence of its concentration. This process suggests that 
the secretion of the growth factors and migration of cells from the leaky vessels 
which allow formation of matrix across which keratinocytes proliferate and 
capillaries form are invariably under the control of NO.  The study by Pipili of 
angiogenesis in-vitro and effect of NO donors has shown that it caused a dose-
dependent inhibition of angiogenesis. It is suggested that NO exerts its anti-
angiogenic effect as it is anti proliferative on endothelial cells through cGMP. 
1.5.2.3 Matrix remodeling 
Fibroplasia and extracellular matrix deposition are under the direct influence of NO 
concentration. NO phenotypically induces wound fibroblasts to myofibroblasts 
which possess increased capacity to secrete collagen and increased contractile 
characteristics.  This helps the wound to heal and the scar to contract. NO secretion 
by fibroblasts starts as early as 3 days and is seen upto 21 days (Michael Schaffer, 
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1997). The wound fibroblasts are stimulated to synthesize NO by a number of 
cytokines (Beer H. D, 2000). Thus the major effect of NO on fibroblasts seems to be 
on the synthetic function. The increased concentration of NO in wound might 
negatively affect collagen secretion. The synthesis of collagen involves an important 
rate limiting step i.e hydroxylation of proline. The enzyme proline hydroxylase is the 
key enzyme in this step (Cao M, 1997). Certain evidences prove that NO may 
inactivate the enzyme by reacting with the Fe radical, as NO is found to inhibit the 
Oxygenase group of enzymes. This is brought about by the formation of Fe- nitrosyl 
complexes. The other possibility is that NOS and prolyl hydroxylase might compete 
for the free available oxygen. Thus NOS being highly reactive might decrease the 
available oxygen to prolyl hydroxylase, resulting in low collagen synthesis. One of 
the strong evidences suggesting that NO decreases wound healing is the observation 
of the fact that endotoxins inhibit wound healing and increases NO production. In 
another different observation it is found that nitric oxide promotes fibroblast 
proliferation (Michael Schaffer, 1997). The net effect on collagen metabolism could 
be direct or indirect by the involvement of the matrix metalloproteinases. In a 
separate observation a strong relation has been seen between the release of IL-1 and 
enhanced expression of iNOS mRNA and matrix-metalloproteinases(George 
Murrel, 1995). The ubiquitous transcription factor NF κB increases expression of 
genes for many enzymes, cytokines and adhesion molecules. NO exerts a negative 
feed back effect on NF KB. Thus the production of inflammatory cytokines and 
other enzymes are decreased with the inhibition of NF κB (Takahashi S, 2001). This 
stands in the favour of the fact that NO enhances wound collagen synthesis. There 
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are various and opposite observations of NO expression and diabetic wound (Jude 
E. B, 1991). In one set of experiments observers have seen a decreased expression of 
NO in diabetes whereas the other group has observed an increase. The variation 
could be related to the models as the former was on an animal model and the later 
on human diabetic foot ulcers (DFU). NOS and in turn NO expression is higher in 
DFU than that in the normal skin. The local cytokine concentration also determines 
the activity of NOS. There has been substantial evidence as regards to the inverse 
relation between transforming growth factor β (TGFβ). TGFβ increases arginase 
activity and decreases that of NOS (Boutard, 1995). In normal wound healing the 
arginase and NOS pathways are properly controlled and co-ordinated but in 
diabetes both the pathways seem to acting independently. Thus there is no down 
regulation of both the pathways. As a result there is an impaired synthesis of proline 
and NO. The interaction of NO and TGFβ have been demonstrated by Joseph. The 
effect of NO on collagen production is also related to the modulation of cGMP 
activity. cGMP activity is decreased by NO and and this furthur decreases collagen 
synthesis. On the contrary TGFβ, which is inhibitory to cGMP enhances wound 
collagen accumulation. Thus it is suggested that TGF-β inhibits NO which in-turn 
inhibits cGMP, which results in increased collagen synthesis (Chu A. J, 1999).  One 
evidence in support of the decreased NOS in diabetes is that urinary nitrate is 
increased in normal wound healing but is decreased in diabetes-induced animals. 
The only explanation for this contrasting observation is that NOS expression might 
vary depending on the experimental model. Thus there is a possibility of variation in 
expression of NOS in diabetic patients and drug induced diabetes in animals. 
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1.5.3 Pharmacological studies of NO in wound healing 
Previous studies suggest that nitric oxide has a direct influence on all the mediators 
and components of wound healing. It is important for mediation of epithelialization, 
angiogenesis, collagen deposition. Antimicrobial effects of the NO released also help 
in complete wound healing with minimal complications.  So far most of the studies 
done on nitric oxide and wound healing has been either by supplementing Arginine, 
Ornithine and SNAP. In our study we have studied the effects of Nitrosoglutahione 
















1.5.3.1 Nitric Oxide donors previously studied in wound healing 
Agent Experimental 
model Wound Parameter Reference 
Molsidomine I.W. Diabetes (rat) 
 ↑collagen,  
↑ strength, ↑ MMP Witte M.B (2002) 
NO releasing PVA sponge 
(dressing) 
I.W. Diabetes 
(mouse) ↑ wound contraction 
Kristyn.S Bohl 
(2002) 





Vasodilation Hardwick (2001) 
HCT-3012 (NO-NSAID) I.W,  (rat) ↑ Collagen Muscara M N (2000)  
Sodium nitroprusside * I.W  (rat) ↓ collagen Shukla A (1999) 
Sodium nitroprusside Diabetic leg ulcer 
(rat) 
↑ accumulation of 
antimicrobial in ulcer 
Shree.E.Cross 
(1996) 
Nitrosoglutathione Keratinocyte culture 
↑ proliferation, 
↑VEGF  
Frank .S (1999) 
 
Glyceryl trinitrite Anal fissures  ↑ healing Lund J N (1997) 
Polyethyleneimine/NO * 






L-Arginine  I.W (human) ↑ lymphocyte immune response 
Adrian Barbul 
(1990) 





L-Arginine Full-thickness Burns (Rat) 





L-Arginine I.W, iNOS knockout (mouse) No improvement Shi H P (2000) 
L-Arginine I.W,  (rat) ↓ collagen Shukla A (1999) 
Ornithine I.W, iNOS  knockout (mouse) 
↑collagen 
↑ strength Shi H P (2002) 
SNAP I.W, iNOS knockout (mouse) 
↑collagen 
 Shi H P (2001) 
INOS transfection 
(cationic) I.W. (rat) 
↑collagen 
 





deficient mice ↑ rate of healing 
Yamasaki K 
(1998) 
DETA-Nonoate, NP, SIN-1 





GSNO & DETA-Nonoate HaCaT keratinocyte ↑ proliferation 
Stefan Frank 
(2000) 
Table 1.5: Summary of previous studies on the effects of NO donors in wound 
healing. I. W. indicates incisional model. * indicates the reports which describe 
inhibition of collagen deposition by NO donors. @ is the only report which describes 
the effect of NO donor on wound concentration. 
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1.5.3.2 Nitric Oxide inhibitors previously studied in wound healing 
Agent  (NO 
inhibition) Experimental model Wound parameter Reference 







Full thickness burns 
(rat) No effect 
Lindblom.L. 
(2000) 
L-NAME * I.W (rat) ↑ collagen Shukla A (1999) 
L-NIL  Keratinocytes ↓ VEGF Frank S (1999) 
L-NMMA Keratinocytes ↓ VEGF Frank S (1999) 
AG I.W (rat) ↓ collagen Michael Schaffer (1999) 
SMITU I.W (rat) ↓ collagen Michael Schaffer (1999 
L-NAME  I.W (rat) No effect Michael Schaffer (1999) 
L-NMMA I.W (rat) No effect Michael Schaffer (1999) 
L-NMMA Sponges from wounds (in-vitro) 




Tacrolimus I.W (rat) ↓ collagen Michael schaffer (1998) 
EGF @ Keratinocytes Increased proliferation Heck D.E (1992) 
iNOS knockout I.W (mouse) No change Most D (2002) 
iNOS knockout I.W (mouse) ↓ collagen ↓strength Shi H P (2002) 
iNOS knockout Fibroblast populated Collagen gel  ↓ contraction Shi H P (2001) 




Table 1.6: Summary of previous studies on the effects of NO inhibitors in wound 
healing. I. W. indicates incisional model. * is the only report where an iNOS 
inhibitor has improved wound collagen content. @ is the study in which EGF has 







These are the sulfur analogues of the alkyl nitrites. Due to the widespread presence 
of cystiene in most of the tissues also the bioactive peptides these compounds are 
readily distributed in the tissues. Nitrosothiols may be formed by nitrosation 
reactions thiols (RSH + HONO →RS-N=O +H2O) but alternatively thiols react with 
NO directly and form nitrosothiols. The release of NO from these compounds is by 
spontaneous dissociation or one electron reduction. The storage of NO in-vivo is 
maintained by the interconversion of nitrosothiols and NO by various biochemical 
reactions. The main forms of nitrosothiols in the blood are S-nitrosocystiene, S-
nitrosoglutathione and S-nitrosoalbumin. These compounds are involved as the 
active intermediates in several NO dissociation of other NO donor compounds. 
1.5.3.4 Interaction of Nitric Oxide with antioxidants. 
NO is a highly toxic compound present in every cell. Antioxidant systems counteract 
all the destructive pathways. Ascorbic acid rapidly detoxifies the NO produced. 
Glutathione effectively reacts with NO and acts as an efficient intracellular NO 
antagonist. Majority of the NO scavenging by GSH is undertaken in the 
mitochondrial matrix. GSH inhibits the peroxynitite –mediated nitration of 
tyrosine. N2O3 also reacts with glutathione yielding S-nitrosoglutathione (Goldstein 
and Czapski 1996). This is found to have protective roles in preventing nitrosation 
of amines ( David A. Wink, 1996). The other secondary antioxidant mechanisms 
that enhance protection against NO mediated cellular damages are Vitamin E, β-
carotene and carotenoids. All these antioxidants are found to have excellent 
synergistic effects in cell protection against nitrogen dioxide (Bohm, 1998). GSH is 
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abundantly present in the cytoplasm and the NO released intracellularly reacts with 
GSH forming GSNO.  
 
 
2.NO + O2 →2.NO2  
.NO + .NO2 →N2O3  
 GSH+ N2O3 →GSNO + HNO2 
 
The reaction of NO with GSH is described by the reaction above (Neil Hogg, 1996). 
GSH in the cytoplasm and mitochondria reacts with NO and avoid damaging side 


























Nitric oxide is a biologically active messenger molecule important in the 
regulation of critical cellular functions. The cellular effects of Nitric Oxide are 
influenced by the presence of glutathione, an anti-oxidant. We hypothesize that 
administration of NO donors containing both NO and glutathione positively 
regulate wound healing. 
1) A combination of NO and GSH could regulate the cellular responses due to 
injury by influencing the activity of enzymes involved in extracellular 
metabolism (MMPs) 
2) The maintenance of appropriate levels of NO and GSH could enhance wound 
collagen content by regulating the activity of MMP’s  
3) Administration of nitrosoglutathione a compound which contains both NO 
and GSH components facilitates wound healing by improving collagen 


































 ↑ rate of healing, 
↑Strength,   
The hypothesized role of S-nitrosoglutathione in a cell. The proposed
beneficial effects are in the form of increased collagen content, improvement
in the rate of wound contraction and biomechanical strength. GSSG is the
oxidized state of glutathione which is formed by the interaction of GSH and















3.0 Materials and Methods 
 
3.1 Materials 
3.1.1 Chemicals and reagents  
3.1.1.1 Anaesthetic agents 
Hypnorm was purchased from Jansen Pharmaceutica, Beerse, Belgium and 
Dormicum was purchased from, Roche, Basel, Switzerland.  
3.1.1.2 General Chemicals  
Merck & Co., Inc. (U.S.A) 
Ammonium Chloride 
Calcium Chloride 
















Triton X-100  
p-dimethylaminobenzaldehyde 
Glycerol 
3.1.1.3 Other Chemicals 
Calbiochem - Novabiochem Corp., (U.S.A) 
S-Nitrosoglutahione (GSNO)  
S-Nitroso-N-acetyl-D-penicillamine (SNAP) 
Leo Pharmaceuticals (Ballerup, Denmark) 
Heparin sodium 
3.1.1.4 Biological products 
iNOS and eNOS monoclonal antimouse IgG antibodies (Transduction Laboratories 
KY, USA). 
MMP2 (Ab-1) and MMP9 (Ab-7) antibodies (Neomarkers CA, USA).  
Vectastain, mouse and Rabbit IgG kits (Vecta Laboratories, CA, USA).  
Bovine anti-mouse IgG1 FITC as a isotype control cat. no MCA 1421 (Serotec Inc., 
NC, USA).  
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Mouse anti-rat MHC class I FITC cat no. MCA 51T (Serotec Inc., NC, USA). 
Mouse anti-rat IA FITC cat. no MCA 46 FT (Serotec Inc., NC, USA).  
Mouse anti rat CD 54 RPE cat. no 773 PE (Serotec Inc., NC, USA).  
Protein assay kit (Bio-rad, Hercules, CA, USA). 
Fetal Bovine Serum (Gibco-BRL). 
Trypsin-EDTA, DMEM and Penicillin-Streptomycin (Sigma, USA). 
3.1.1.5 Commercial kits 
Type IV Collagenase activity assay kit cat. no ECM 478 (Chemicon Intl Inc. 
Temecula, USA). 
Glutathione assay kit cat. No. 703002 (Cayman chemical, USA). 
1 part of dormicum (Roche, Basel, Switzerland). 
3.1.1.6 Instruments 
Instron material testing machine (Massachusetts, USA) 
Schimadzu Spectrophotometer (Kyoto, Japan) 
Fluorescence Spectrophotometer LS 50B (Perkin Elmer Inc., USA) 
Microfilter tubes (Whatman Intl Ltd., England) 
3.1.2 Experimental animals 
Sprague Dawley male rats were chosen for this study. They were between the age 
group of 8-10 weeks and weighed around 200-250gms. All the animals were 
obtained from Laboratory Animal Center (Sembawang, Singapore). The animals 




3.2.1 Animal Study 
The effect of drugs on wound healing was studied using intact animal models.  All 
animal experiments were conducted according to the institutional guiding principles 
for animal research, National University of Singapore.  The weight of the animals 
was measured once every 3 days as a general health indicator. Constant weight gain 
and activity were the indices of general health. The official approval of animal 
experiments is given in the Appendix A. 
3.2.1.1 Animal care 
Sprague Dawley male rats, weighing 200-250 gm, obtained from the Laboratory 
Animals Centre (LAC, Sembawang, Singapore) were used throughout the study. To 
avoid overcrowding each rat was individually caged. All animals were kept at the 
Animal Holding Unit (National University of Singapore) and were allowed to 
acclimatize for a duration of 1 week before operation. All rats were weighed prior to 
the study, and thereafter monthly till the date of sacrifice.  
All animals were kept in a photo-periodic room with 12 hour day/night cycle. 
Animals were kept in artificial light. Animals were fed on standard laboratory chow 
and water given ad libitum. All procedures were performed between hour 8 and 12 
of the day cycle. The room temperature was maintained at 21°C with a relative 
humidity of about 50%. Soft white wood shavings were used as bedding material. 
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 3.2.1.2 Grouping of animals based on wound models 
Experimental animals were grouped based on two separate models of wound for the 
purpose of this study. They were 1) excisional square wound model and 2) Incisional 
wound model. These two groups were further divided into various treatment groups 
as described below. 
3.2.1.2.1 Excisional Square wound group 
The excisional wound model was adopted to compare the overall effects of Nitric 
oxide donor and inhibitor on wound healing. Totally, Eighteen rats underwent 
square wound explants on their dorsal surface. They were divided into control, 
GSNO and AG group, with 6 animals ‘n’ in each group. 
3.2.1.2.2 Incisional wound group 
In-order to examine the effects of drug treatments at different time points, the 
animals underwent incisional wound. This allows to sample out the reparative tissue 
deposited between the margins at earlier time points. The incisional wound groups 
consisted of 4 different time points at which the scar tissue was harvested. The time 
points were 3, 5, 7 and 10 days after wounding. At each time point there were 6 
animals (n=6) that were sacrificed from each group. Therefore there were twenty-
four animals in each group. The study design involved administration of Saline 
(control), GSNO, GSH, AG and SNAP. Therefore a total of one hundred and twenty 
animals were recruited for our experiments  
 
 70 
3.2.1.3 Surgical Procedure  
3.2.1.3.1 Animal Anaesthesia  
All rats included in the study requiring tranquillisation were anaesthetised using a 
Clinical Research Center (CRC) cocktail obtained with the consent of the in-house 
veterinary surgeon.  This cocktail containing 1 part of Hypnorm, 1 part of 
Dormicum and 2 parts of saline was used for injection.  The aneasthetic was 
administered at a dose of 0.1ml/100mg kg body weight.  
3.2.1.3.2 Square wound model 
To evaluate the effect of the agents on wound healing, the changes in a square 
wound model were examined. This model is representative of all the phases of 
wound healing. Following acclimatization for a week, the animals were subjected for 
the operative procedure. The hair on the dorsum of the anaesthetized rats was 
shaved with an electrical shaver. Full thickness square wounds measuring 15mm X 
15mm were made by excising the skin within the confines of square down to the 
level of the panniculous carnosus (Fig. 3.1). All dissections were performed using a 
size 15 blade and care was taken not to contuse the borders. The wounds were left to 
heal for 12-14 days on their own without any dressing being applied. The animals 
were placed in individual cages. The outline of the wounds were measured every 24 
hrs. The animals were held immobile with head covered and the length (L) and 
breadth (B) of the wound was measured and the area calculated (LXB). The rate of 
contraction was obtained by plotting the log of area Vs time.  
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The gradient of each regression line is the log co-efficient of wound contraction k, 
for each animal. The k value of each wound was taken as a measure of the rate of 




























Square excisional wound model. Four excisional wounds, each measuring 
15mm were created. Daily measurements of the area (length and breadth) 
und were done in the same position. 
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3.2.1.3.3 Incisional model 
Each animal underwent a seven-centimeter long dorsal incision along the head-tail 
axis, through the depth of the epidermis, dermis and panniculous carnosus under 
hypnorm anaesthesia (Fig. 3.2). The margins were properly approximated and 
sutured with intermittent 3-0 silk surgical sutures. The animals were observed till 













Fig. 3.2: Incisional wound model. 7-8 cms long incisions were made on the dorsum 
of the rats. Wounds were closed by interrupted sutures and the scars were harvested 







3.2.1.3.4 Intra-abdominal catheterization 
Animals were anaesthetized, their abdominal wall was shaved and a small incision 
was made in the anterior wall. The peritoneum was opened and a silastic tube with a 
wide perforated tip was inserted into the abdomen under sterile conditions (Fig. 
3.3). The tube was then drawn through the dorsum under the skin and let out at the 
top of the head. The free end was corked with a metallic stopper. The tube was 
sealed with a dental cement on the skull. The catheters were flushed with saline and 
the animals were kept under observation. The catheter exiting from the skull were 
flushed again with saline on the following day and 500µl of peritoneal fluid was 












Fig. 3.3: Intra-abdominal catheterization. A silastic tube was placed in the 





3.2.1.3.5 Sephanous vein catheterization 
A different catheter was inserted into the sephanous veins of the animals. Briefly the 
inguinal region was dissected out and the sephanous vein was identified. The vein 
was cannulated by a thin elastin tube attached to P10 silastic tube. The catheter was 
drawn up to the base of the skull along with that from the abdomen. Both the 
catheters were secured safe at the skull base by dental cement.  
3.2.1.4 Treatment of animals with pharmacological agents 
Control animals 
Animals were administered normal saline, which was the vehicle (solvent) for all the 
other drugs. 
 
Nitric oxide donors 
Nitrosoglutathione, (GSNO) and S-nitroso-N-Acetylpenicillamine (SNAP) was   
administered i.p to animals at 24 hour intervals at 0.3 mg kg-1 body weight. 
 
Nitric oxide inhibitor 
Aminoguanidine was administered i.p to animals at 24 hour intervals at a dosage of 
100 mg/kg body weight. 
 
Reduced glutathione 
Reduced glutathione was administered i.p to animals at 24 hour intervals at 0.3 


























S-Nitroso N-acetyl-DL-penicillamine  (SNAP)  
 
 Fig 3.5: Chemical structure of N-Acetyl-DL-penicillamine (NAP) and










Fig 3.6: Chemical structure of aminoguanidine and L-arginine 
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 3.2.1.5 Sampling of the scar tissue 
The scar tissue from the animals was excised completely. The surrounding normal 
tissue in the scar sample was clearly dissected out. The scar was divided into four 
equal parts for A) measurement of collagen content B) MMP activity assay C) 
Nitrate and Nitrite measurement and D) Glutathione content. The following 
diagram represents schematic plan of scar excision.  
3.2.1.6 Storage of the scar tissue 
Samples were snap frozen in liquid nitrogen and stored at –80°C in labeled cryovials 
for MMP activity assay, hydroxyproline estimation, nitrite and nitrate assay and 
glutathione estimation. Few samples of the same tissue were placed in plastic 
cassettes and preserved in 4% formalin for preparation of paraffin blocks. 
3.2.2 Determination of Collagen content 
Hydroxyproline (Hyp) is a post-translational product of proline hydroxylation 
catalyzed by an enzyme prolylhydroxylase. The occurrence of this imino acid is 
thought to be confined almost exclusively to the connective tissue collagen (Nemethy, 
1986). Because of its restricted and unique distribution in connective tissue collagen, 
the metabolism of collagen and its regulation is conveniently studied by measuring 
the Hyp content in a number of normal and clinical situation. In this study, the Hyp 
content has been measured which indicates the total collagen content of the scar 
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tissue. This imino acid was quantified by a spectrophotometric method (Woessner 
1961) as described below.  
Experiment: Pre-weighed frozen scar tissue was treated with 6 N HCl for 30 
minutes at 1300C in a microwave oven. The solution thus obtained was neutralized 
with 1M Sodium hydroxide. The neutral solution was reduced with chloramine T in 
acetate buffer. Following 20 minutes of incubation at room temperature, perchloric 
acid was added to furthur neutralize the solution. Para-aminobezaldehyde dissolved 
in methyl-cellosolve was added to derivatize hydroxyproline. The absorbance was 
read at 557 nm in a Shimadzu spetrophotometer. The hydroxyproline content was 
read off a standard straight line obtained using known concentrations of the 
compound. Therefore, collagen content was quantified for each sample of the scar 
tissue from each group of animals. 
 
3.2.3 Biomechanical testing 
The biomechanical testing of the tissue clearly provides information regarding it’s 
material properties. The study of the effects of the treatment on the material 
property indicates the change in the quality of the scar.  The instron materials 
testing machine tests the material property of the scar. The parameters that are 
being measured are a) Load to failure and b) stiffness of the scar.  
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3.2.3.1 Sample preparation 
The specimen to be tested is prepared in a manner that is appropriate to conduct a 
load displacement measurement of the scar. Fresh rectangular strips of skin (1cm) 
with the scar at the mid-point were harvested from anaesthetised animals, following 
wounding (both 5 days & 10 days). The biomechanical testing is done at 5 and 10 
day intervals as these are the two time points at which the collagen deposition is 
significant and the remodeling of the new matrix takes place. For biomechanical 
testing the scars are harvested from the caudal end of the linear scar on the back of 
the rats. The strip of skin, orthogonal to the axis of the scar, was taken to ensure 
















 ntal set-up for biomechanical testing. Fresh skin for testing and 
es to enhance the gripping by the materials testing machine are 
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3.2.3.2 Tensile strength measurement  
The specimen was held between clamps of an INSTRON 5543 materials testing 
system (Fig 3.7 & 3.8) with a 500 N load cell. The accuracy of this machine was upto 
1% of maximum readings i.e. 2N. The clamps were modified to include a perspex 
and sandpaper interface to optimize specimen grip with minimum damage to the 
tissue at the grip site during testing. The gauge length (distance between the clamps) 
for each specimen was set at 15mm with the specimen positioned to ensure that the 
horizontal scar-line lay in the center, equidistant from either of the clamped ends. 
Uniaxial load at a deformation rate of 25mm/min was applied along the length of the 
skin (Paul R.G, 1997). From the load-deformation curves obtained after the 















 ls testing machine. Skin mounted between the clamps of the 
 is seen in this picture. 
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3.2.4 Tissue protein measurement 
 
The Bio-Rad protein assay, based on the Bradford method was adopted to 
determine the protein content in the tissues. All the protein assays were done 
according to the standard procedure provided by Bio-Rad Protein assay instruction 
manual. The microtiter plate protocol was followed. The Bio-Rad reagent is diluted 
1:5 with double distilled water. The dye is filtered and stored at room temperature. 
Protein standards from bovine serum albumin are prepared between a range of 0.05 
mg/ml – 0.5mg/ml. 10 µl of standard or test protein solution is added into each well 
of a microtiter plate. 200 µl of diluted reagent is added to each well containing the 
samples or standards. The plate is incubated at room temperature for 5 minutes and 
the absorbance was read at 595 nm in a Shimadzu (Japan) spectrophotometer. The 
readings are tabulated in Graphpad Prism software (USA) and protein 
concentration of the samples are derived from standard curve obtained by plotting 
the absorbance of standards against concentration. 
3.2.5 Matrix metalloproteinase activity assay 
Gelatinases are the key enzymes in breakdown pathway of collagen. Extended 
activity of MMP’s in healing environment inhibits re-epithelialisation and matrix 
deposition. As NO and GSH are effective mediators of inflammation, and a high 
MMP activity is seen in this phase, it is important to examine the effects of these 
molecules on Gelatinase activity. 
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Fluorogenic peptide substrate assay for activity of matrix metalloproteinase in the 
scar samples was carried out. The first mammalian MMP peptidase activities 
demonstrated were cleavage of Dnp-Pro-Leu-Gly~Ile-Ala_gly-D-Arg and Dnp-Pro-
Gln-Gly~Ile-Ala-Gly-Gln-D-Arg by MMP 2 (Seltzer, 1981). Fluorogenic substrates 
provide a particularly convenient enzyme assay method. The basic principle that 
governs the method is as follows: When the substrate is cleaved by the enzyme, 
diffusion of the donor-containing substrate fragment cleaves away from the 
acceptor-containing substrate fragment results in loss of energy transfer and 
subsequent appearance of fluorescence.  This method was adopted to measure the 
gelatinase activity in the scars of animals treated with various pharmacological 
agents. 
3.2.5.1 Extraction of MMP’s from the scar tissue 
Preweighed fresh frozen scar tissue was utilized for the activity assay. The 
specimens were pulverized in liquid nitrogen and then homogenized in buffer 
containing 0.25% triton X-100 in 0.01M CaCl2. The homogenized sample was 
centrifuged at 6000 g and the pellet was resuspended in 0.1 M CaCl2, 0.15 M Nacl 
and 0.05 M Tris HCl (pH 7.5). The suspension was heated for 6 minutes at 60°C, 
chilled and centrifuged at 20,000 g. The extract was reduced with 2 mM di-
thiothrietol for 30 minutes at 37°C and alkylated with 5 mM iodoacetamide for 30 
minutes at 37°C. The samples were filtered through microfilter tubes (Whatman intl 




3.2.5.2 Gelatinase (MMP) activity assay 
The assay was carried out on the scar samples of all the animals according to the 
manufacturers instructions (Appendix C). The extracted MMP’s were immediately 
activated by 0.5 mM amino phenyl mercurial acetate (APMA). The fluorescent 
collagen substrate provided in the Gelatinase assay kit is incubated with 25 µl of the 
sample.  The fluorescence of the reaction mixture is read in a luminescence 
spectrometer LS 50 B (Perkin Elmer England). The readings are calculated 
according to the formula 
  
FS-FB / FT-FB   x    1 /  Reaction time (mins)   x    Yµg of substrate / (X ml sample / tube) 
   
Where FS implies Florescence of the sample, FB is the fluorescence of the blank and 
FT is the fluorescence of the total.  
The result is expressed as units where in each unit is the activity of the enzyme per 
µg of collagen substrate added. 
 
3.2.6 Determination of Total Nitrite 
The main breakdown products of Nitrosothiols are nitric oxide which rapidly forms 
peroxynitrite and inturn nitrite and nitrate. Therefore the end-products of NO 
metabolism were measured through Griess reaction. 
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3.2.6.1 Determination of Nitrite in wound lysates 
The stable NO oxidation product, nitrite was determined in wound homogenates by 
the Griess reaction. Skin samples were homogenized in lysis buffer containing 2% 
triton X-100, 40 mM tris HCl (Merk, Germany), pH 8.0, 274mM NaCl, 20% 
glycerol (Merk, Germany), 10mM phenylmethylsulfonyl fluoride and 30(g/ml 
leupeptin. The tissue extract was cleared by centrifugation and the supernatant was 
diluted with equal volume of water. The extract thus diluted was centrifuged at 
100,000 g for 30 minutes. The supernatant was further filtered through ultra spin 
cups (Whatman intl Ltd England) with 30 kda cut off. The eluate obtained was 
analysed for the nitrite content. Sulphanilamide 50 µl and 50 µl N-
naphthylendiamine dihydrochloride were added to 50 µl of sample. Each reaction 
mixture contained 0.1 U/ml nitrate reductase (Roche,USA), 5(M FAD, 0.03mM 
NADPH for the complete reduction of nitrate. The absorbance of the reaction 
mixture was read at 540 nm after 15 minutes of incubation. 
3.2.6.2 Determination of Nitrite in plasma 
Blood was obtained from the rats by sephanous vein catheterization. 500 µl of blood 
samples was collected in microtainer tubes (Becton Dickinson) containing EDTA. 
The samples were centrifuged at 10,000 g and the supernatant plasma was collected. 
The plasma was diluted with equal volume of distilled water and filtered through 
microfilters (Whatman Intl UK). The eluate was transferred into fresh eppendorf 
tubes and stored at –20°C until further procedure. 40 µl of the sample was used for 
the nitrite assay. The readings obtained were further standardized against the 
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protein content. The results are expressed as mM of nitrite / mg of protein content 
in the tissue. 
3.2.7 Glutathione assay 
Glutathione is one of the important molecules present in the cells and it readily 
interacts with NO-. Therefore in any study involving the usage of NO modulating 
drugs, the effect on the GSH status has to be monitored. The scar glutathione was 
quantified by Cayman's GSH assay kit. This utilizes the recycling method of 
DSTNB by glutathione reductase for the quantification of GSH. The sulfhydryl 
group of GSH reacts with 5,5'-dithiobis-2-nitrobenzoic acid (DTNB, Ellman's 
reagent) and produces a yellow colored 5-thio-2 nitrobenzoic acid (TNB). The mixed 
disulfide, GSTNB (between GSH and TNB) that is concomitantly produced, is 
reduced by glutathione reductase to recycle the GSH and (produce more TNB. The 
rate of TNB production is directly proportional to this recycling reaction, which is 
in turn proportional to the concentration of GSH in the sample. Measurement of the 
absorbance of TNB at 405 or 412 nm provides an accurate estimation of GSH in the 






Fig. 3.9: Schematic repr
  
esentation of DTNB recycling in glutathione assay. 
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3.2.7.1 Sample preparation 
The frozen scar tissues were pulverized and homogenized in 1 mM tris HCl, pH 6.5. 
The samples were centrifuged at 11,000 g and the supernatant was aliquoted into 
labeled microcentrifuge tubes. The samples thus prepared were subjected for de-
proteination.  
3.2.7.2 De-proteination 
The samples were de-proteinated by metaphosphoric acid (MPA). Equal volumes of 
MPA is added to the sample and incubated for 5 minutes. The mixture is 
centrifuged at 2000 g for 5 minutes and the supernatant is aliquoted. 50 µl of 
Triethanolamine is added to the supernatant. The sample is ready for Glutahione 
quantification. The procedure is followed according to the manufacturers 
instruction (Appendix D). The absorbance is measured at 412 nm. 
 
3.2.8 Flow cytometry of peritoneal cells 
Nitric oxide is a secondary signaling molecule that  influences the activity of immune 
cells. Following administration of NO donors or NOS inhibitors, changes in the 
immune response and macrophage activity are possible. So in order to characterize 
the effects of the drugs on the peritoneal immune cells we studied the expression of 
MHC Class I, Class II and ICAM-1, which indicate alteration in immune response.  
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3.2.8.1 Sample collection 
The peritoneal washing obtained after 24 hours of abdominal catheterization is used 
in this method. Following the abdominal catheterization rats were allowed to 
recover overnight. 24 hrs after catheterization 1ml of PBS was flushed into the 
catheter and same amount of fluid was withdrawn carefully into labeled microfuge 
tubes.  
3.2.8.2 Fluorescent staining 
The effects of GSNO on the MHC Class I, Class II and ICAM-1 (CD54) expression 
on peritoneal cells was monitored by flow cytometry. Peritoneal lavage was 
centrifuged at 600 g for 10 minutes. The cell pellet was resuspended in RBC lysis 
buffer and incubated at 4°C for 10 minutes. The sample is again centrifuged at 600 
g at 4 0C for 10 minutes and the cell pellet is resuspended in PBS containing 1% 
BSA. The cells were incubated in MHC Class I, Class II and ICAM-1 fluorescent 
antibodies at a concentration of 10 µl/ 106 cells. The samples were incubated for 30 
minutes. FITC conjugated Isotype control mouse IgG1, was used in this study. Cells 
were pelleted and washed twice inPBS-BSA and furthur fixed in 1% 
Paraformaldehyde. The stained cells were analysed by flow cytometry on a Becton 
Dickinson FACStation  using  the winMDI software, version 2.8, (The Scripps 




The effects of treatment were monitored histologically by H&E staining and 
immunohistochemistry. By H&E method, changes in the dermal or the epidermal 
morphology, inflammatory infiltration and changes in the capillary network can be 
appropriately studied. Immunohistochemical staning provides information on the 
distribution of the molecule at microanatomic level and variation in the pattern of 
expression can be noted.  
3.2.9.1 Preparation of histological sections 
The animals were sacrificed and the scars of all animals were excised, placed in 
cassettes and fixed in 10% formalin for histological examination. Two scars and one 
normal skin biopsy were taken from the dorsum of each animal. After processing, 
the samples were transferred to an Lieca embedding machine for preparing the 
paraffin blocks. The tissues were embedded and sectioned into 4 µm sections. 
3.2.9.2 Hematoxylin and eosin staining 
Slides were deparaffinized in xylene and rehydrated in decreasing concentrations of 
alcohol. The deparaffinized specimens were placed in eosin for 5 minutes. 
Immediately the slides were placed in hematoxylin solution for 3 minutes. The slides 
were then washed under running water till all the excess stains were washed away 
clearly. The slides were dehydrated in increasing concentrations of alcohol and 
xylene. The samples were mounted and coverslipped in Canada balsam. All the 
slides were viewed in Olympus microscope at 20 X and 40 X magnifications. 
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3.2.9.3 Immunocytochemistry 
3.2.9.3.1 MMP immunostaining 
The sections are dewaxed in xylene by immersing thrice. The sections are 
rehydrated through decreasing concentration of ethanol. [Absolute → Absolute → 
90% → 90% → 70% → 70%] followed by immersing in water. Endogenous 
peroxidase activity is blocked by treating the sections with 0.3% hydrogen peroxide 
in methanolfor 30 minutes. The slides are then washed in PBS for 5 minutes. 
Digestion of the sections is done with 0.05% saponin solution for 30 minutes 
followed a thorough wash in PBS for 5 minutes. Non-specific binding is inhibited by 
blocking the sections with normal goat serum for 30 minutes. The excess serum is 
drained and, Avidin is applied for 15 minutes. The slides are drained and again 
treated with Biotin solution for 15 minutes. The slides are washed in PBS for 5 
minutes. MMP primary antibody is applied at a concentration of 1:30 for MMP-9 
and 1: 100 for MMP 2. The antibodies are incubated at room temperature for 2 
hours. [Negative control slides will be treated with PBS]. The slides are further 
washed in PBS for 5 minutes. Biotinylated secondary antibody (goat anti-rabbit) is 
added for 45 minutes to each section. The sections are washed again in PBS for 5 
minutes. Each specimen is treated with ABC reagent for 10 minutes and washed in 
PBS for 5 minutes. Freshly prepared chromogen DAB is applied for 10 minutes. The 
slides are washed well in running water as soon as the brownish discoloration is 
seen. Counterstaining was done with haematoxylin for 5 – 10 seconds.  
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The washed slides are dehydrated in increasing concentration of ethanol [70% → 
70% → 90% → 90% → Absolute → Absolute]. The specimens are immersed in 
clear sections in xylene and mounted and coverslipped. 
3.2.9.3.2 Immunostaining of iNOS and eNOS 
The sections are dewaxed in xylene by immersing thrice. The sections are 
rehydrated through decreasing concentration of ethanol. [Absolute → Absolute → 
90% → 90% → 70% → 70%] followed by immersing in water. Endogenous 
peroxidase activity is blocked by treating the sections with 0.3% hydrogen peroxide 
in methanol for 30 minutes. The slides are then washed in PBS for 5 minutes. 
Digestion of the sections is done with 0.05% saponin solution for 30 minutes 
followed a thorough wash in PBS for 5 minutes. Non-specific binding is inhibited by 
blocking the sections with normal horse serum for 30 minutes. The excess serum is 
drained and furthur, Avidin is applied for 15 minutes. The slides are drained and 
again treated with Biotin solution for 15 minutes. The slides are washed in PBS for 5 
minutes. iNOS and eNOS primary antibodies are applied at a concentration of 1:30 
and 1:100 respectively. All the slides were incubated overnight at 4°C. [Negative 
control slides will be treated with PBS]. The slides are further washed in PBS for 5 
minutes. Biotinylated secondary antibody is added for 45 minutes to each section. 
The sections are washed again in PBS for 5 minutes. The sections are treated with 
ABC reagent for 10 minutes and washed in PBS for 5 minutes. Freshly prepared 
chromogen DAB is applied for 10 minutes. The slides are washed well in running 
water as soon as the brownish discoloration is seen. The slides are counterstained 
with haematoxylin for 5 – 10 seconds. The washed slides are dehydrated in 
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increasing concentration of ethanol [70% → 70% → 90% → 90% → Absolute → 
Absolute]. The specimens are immersed in clear sections in xylene and mounted and 
coverslipped. The slides are then viewed at 20 X and 40 X magnification. 
3.2.9.3.3 Evaluation of slides 
The present underlying technique was used to evaluate the immunohistochemical 
staining procedures. This method of staining takes into account both the intensity of 
staining in a given high power field and area stained (number of cells) in a high 
power field. All scoring was done based on staining patterns of a minimum 5 high 
power fields that were randomly chosen by the evaluator. The slides were evaluated 
blindly by two individuals and the scores obtained compared to verify the staining 
pattern in a given cell type.  
Scoring: Samples were rated according to a visual score which was calculated by 
adding the scale of intensity of staining to the area of the staining i.e score = 
intensity +area. The intensity of staining had the following scale; 0, no staining of 
the dermal and the epidermal layer, 1+ mild staining; 2+ moderate staining; 3+ 
marked staining. The area of staining was evaluated differently using the following 
scale; 0, no staining of the scar tissue, 1+ <25% of the area stained positive, 2+ 25-
50% positive staining, 3+ 50-75 % positive staining, 4+ >75% positive staining. The 
maximum score awarded was 7 (3+4) and the minimum was 0, indicating complete 
absence of the antigen under study.  
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3.2.10 Statistical analysis 
The parametric data are reported as mean ±standard error of mean (SEM). 
Statistical significance was assessed by one-way ANOVA using Statistical Program 
for Social Sciences version 10 (SPSS Inc. USA). For the analysis of Non-parametric 
data, Kruskal-wallis test for multiple comparisons of Median of each group was 


















4.0 General health of the animals 
The animals were monitored daily for food and water intake. The wounds were 
examined daily and the activity of the animals was monitored. Most of the wounds 
healed without any infection.  The animals were active and a constant weight gain 
was observed.  
4.1 Square wounds 
This model was adopted to investigate the effect of the drugs on the process of 
wound contraction. As an initial step to analyze quantitatively the progress of 
wound repair following administration of a NO donor (GSNO) and an iNOS 
inhibitor, we propose to study the effect of these drugs on wound contraction.  Four 
square wounds were inflicted on each animal and the average area of the four 
wounds was taken as a single reading. This method of measurement was repeated 
three times on each animal. The rate of wound contraction is expressed in terms of 
log of wound area vs. time (Fig. 4.1). A regression line drawn along the points of log 
curve gives the constant co-efficient, which is interpreted as the rate of wound 
healing.  
4.1.1 Gross observation 
The wound area increased marginally over the area of the original template used for 
the first two days. This is a result of the extension forces exerted by the surrounding 
normal skin and its loose attachment to the deep fascia. Between the second and 
third day a sharp decrease in the area of the wounds was observed. After the third 
day, the wound area appeared to decrease at a constant rate, which progressively 
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declined towards tenth to twelfth day. The measurements were all taken from the 
margins of the wounds, which were previously marked by permanent ink while 
creating the wounds. The healing progressed with the scabs drying from the 
periphery. Measurements were taken for a total period of 12 days by which time 
most of the wounds had completely healed (Fig. 4.2). Following complete healing a 
scar with a size smaller than the original wound was observed. The scar was square 
in shape and the edges were elongated. The measurements of the area were 
consistent and repeatable. Each wound was exposed to external environment. The 
ability of the wound to heal in the natural setting, wherein no dressing or any other 
supportive therapy is administered was a part of this study.  
4.1.2 Effects of GSNO on rate of wound contraction 
The log co-efficient (k) which indicates the rate of wound contraction was 0.125 ± 
0.02 in the control group  and 0.234 ± 0.06 in the GSNO group (Fig. 4.2). The rate of 
wound contraction was significantly higher (p< 0.05) in the GSNO treated group 
than the control group. The GSNO and control (saline) treated animals did not 
show any signs of wound infection and the wounds healed normally.  
4.1.3 Effects of AG on wound contraction 
The log co-efficient (k) was 0.09±.0.009 in the AG treated group (Fig. 4.2). The 
administration of AG did not significantly alter the rate of healing. Though the rate 
of healing was decreased in the AG treated group there was no statistical 
significance observed in our study. A trend towards a decrease in the rate of healing 
was seen in the AG treated group. 
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Fig. 4.1: Log curve of wound contraction. T
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Fig. 4.2: Rate of wound contraction in Control, AG and GSNO treated animals. The 
mean rate of wound contraction is represented in this graph (n=6). Error bars 
correspond to SEM and * is statistical significance (p<0.05). Y-axis represents log 








4.2 Biomechanical strength of scars treated with NO donors and 
inhibitors 
The changes in the material properties (Load and stiffness) of the scar following 
treatment with GSNO, SNAP, GSH and AG were measured in an Instron 5543 
materials testing machine. The load deformation curve for each sample was traced 
with the displacement (distance moved) on the X-axis and the force applied on Y-
axis (Fig. 4.3). The load of each sample corresponds to the peak of the graph. The 
stiffness is obtained by measuring the slope of the straight line in the log phase of 
the curve.  
Gross observation: The scars are elastic in the initial phase. Gradually a break 
appears at the site of the scars from the periphery to the center. The point at which 
the scar completely breaks is the end-point of tracing. Maximum strength (load) is 
required when the scar substance has to be broken initially following which, the rest 
of the sample gives way without much resistance. 
The scar properties were characterized in terms of the force required to break the 
newly deposited tissue. This force is described as the load to failure and is expressed 
in Newton (N). Biomechanical testing of the scars was conducted at two time points 
which correspond to a) maximum deposition of extracellular matrix (day 5) and b) 
matrix remodeling (day 10). By 5 days the wounds were not completely healed and 
the granulation tissue did not offer great resistance to the force applied by the 
Instron machine. At the tenth day most of the wounds were totally healed and the 
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Fig 4.3: Load deformation curve of the scars. The X-axis is the displacement (mm) 
and Y-axis is the Load (N). The load displacement curve has various phases 
corresponding to the changes in the tissue, each representing a physical parameter. 
The tissue has the initial toe region with less resistance and a steep resistant region 
of increased load. This is the elastic region and gives the measure of the stiffness of 





4.2.1 Load to failure of the scars 
4.2.1.1 Effects of GSNO, SNAP and GSH on load to failure 
The maximum load to failure of the control group increased from 6.0 ± 0.47 N to 9.8 
±1.51 N from the 5th to the 10th post-wounding day (Fig. 4.4). All the groups showed 
an increase in the load from the 5th to 10th post-wounding day (Table 4.1). The load 
of the GSNO group was significantly higher than the control, SNAP and GSH 
treated scars on the tenth post-wounding day. SNAP and GSH treated groups 
showed no significant difference in the load to failure of the scars.   
4.2.1.2 Effects of AG on load to failure 
The maximum load to failure of AG treated scars was significantly lower (p<0.05) 
than the GSNO treated group at the 10th post-wounding day. 
Treatment 5 Days 10 Days 
Control 6.0  ± 0.47 9.8 ± 1.51 
GSNO 7.84 ± 0.79 e 16.6 ± 2.65 a,c,d,e  
SNAP 5.8 ± 0.15 10.1 ± 1.38 
AG 5.1 ± 0.56 11.39 ± 1.91 
GSH  4.34± 0.47 7.81 ± 1.51 
 
Table 4.1: Load to failure of scars following treatment of GSNO, SNAP, AG and 
GSH. Measurements were taken at 5 and 10 days post-wounding. Results are mean 
± SEM (n=6). The statistical significance p<0.05 is in comparison with a) control, b) 
GSNO, c) SNAP, d) GSH and e) AG. Note that the comparisons were made between 







































































































Fig. 4.4: Load to failure of scars treated with GSNO, SNAP, GSH and AG. Results are mean ± SEM (n=6). The 
statistical significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. Note that 
the comparisons were made between the groups of the same day and error bars correspond to SEM. Y-axis 
represents load to failure (N). 
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4.2.2 Stiffness of the scars 
Stiffness is defined as the maximum resistance offered by the scar to the force 
applied. This is interpreted as the slope of the log phase of the load deformation 
curve (Fig. 4.3). 
4.2.2.1 Effects of GSNO, SNAP and GSH on scar stiffness 
The stiffness of control group was 1.86 ± 0.26 N/mm at the 5th post-wounding day 
and 2.87 ± 0.45 N/mm at tenth post-wounding day  (Fig.4.5). The stiffness of the 
GSNO group was significantly higher than the GSH group at 5 days. After 10 days 
of healing the stiffness of GSNO treated group was significantly higher than the 
control, SNAP and GSH groups (Table 4.2). SNAP treated group showed no 
significant change whereas GSH group had lower stiffness than the control, SNAP 
and GSNO groups at the tenth day (p<0.05). 
4.2.2.2 Effects of AG on scar stiffness 
AG treated scars had lower stiffness compared to GSNO group on the fifth day 
(p<0.05) (Fig. 4.5). After 10 days of treatment AG had significantly lower stiffness 










Treatment 5 Days 10 Days 
Control 1.86 ± 0.26 2.87 ± 0.45 
GSNO 2.82 ± 0.60 d,e 4.56 ± 0.64 a,d,e 
SNAP 2.03 ± 0.16 e 2.91 ± 0. 52 e 
AG 1.54 ± 0.16 1.7 ± 0.491 a 




Table 4.2: Stiffness of scars following treatment of GSNO, SNAP, AG and GSH. 
Measurements were taken at 5 and 10 days post-wounding. Results are mean ± SEM 
(n=6). The statistical significance p<0.05 is in comparison with a) control, b) GSNO, 
c) SNAP, d) GSH and e) AG. Note that the comparisons were made between the 

































































































































ig. 4.5: Stiffness of scars treated with GSNO, SNAP, GSH and AG. Results are mean ± SEM (n=6). The statistical
ignificance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. Note that the







































4.6: Sample tracing of load displacement of a 5 day Control scar. X-axis 
esents displacement (mm) and Y-axis is the load to failure (N). 
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4.3 Collagen content 
Hydroxyproline, which is the main component of collagen, is quantified in the scars 
of all groups of animals. The total hydroxyproline was quantified with reference to 
the standard straight-line obtained by plotting various known concentrations of the 
compound (Fig. 4.7). The samples of scars at earlier days consisted mainly of the 
granulation tissue. Any scab formed was discarded before preserving the tissue. 
Care was taken not to involve the sleeve of normal skin at the margins. The method 
was repeatable and consistent readings were obtained through out the procedure. 
The two time points day 5 and day 10 were chosen as they represent the points of 
peak collagen deposition and remodeling (section 1.4.2). The hydroxyproline content 
is expressed in terms of microgram per mg of the wet weight of the scar tissue. As 
hydroxyproline is the indicator of collagen content henceforth the terms 
hydroxyproline and collagen will be used as synonyms.  
4.3.1 Effects of GSNO, SNAP and GSH on collagen content 
The collagen content of control scars was 0.856 ± 0.104 µg/mg tissue at 5 days post-
wounding and 0.436 ± 0.07 µg/mg after 10 days of wounding (Fig. 4.8). This is 
similar to the previously reported observations that the collagen deposition 
decreases after 5-7 days of healing (Zeitz.M, 1978). The collagen deposition 
characteristics of the GSNO treated animals were similar to that of the control 
group, but the collagen content was higher by 52% on the 5th post-wounding day 
and 47% higher on the tenth post-wounding day (Table 4.3). The SNAP treated 
group had significantly lower collagen content than the control and GSNO groups 
on the 5th post-wounding day (p<0.05). By the tenth post-wounding day no 
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significant differences were observed in the collagen content of the SNAP group. 
The collagen content of the GSH treated scars was lower by 76% on the 5th post-
wounding day compared to the control group (p<0.05) and by the 10th day, it 
reaches control levels. 
4.3.2 Effects of AG on collagen content 
The NOS inhibitor, AG treated group had collagen content lower than the control 
and GSNO treated scars on the 5th post-wounding day (p<0.05). By the tenth post-
wounding day collagen content was significantly lower than the GSNO group 
(p<0.05). 
 
Group 5 Days 10 Days 
Control 0.856 ± 0.10 0.436 ±0.07  
GSNO 1.38 ±0.23 a,c,d,e 0.83 ±0.17 a 
SNAP 0.459 ±0.16 a 0.561 ±0.07 
GSH 0.204 ±0.04 a 0.65 ±0.15 
AG 0.474 ±0.08 a 0.484 ±0.13 b 
 
Table 4.3: Collagen content of scars. The collagen content (µg/mg) in the scars 
treated with GSNO, SNAP, GSH and AG are shown in this table. Results are mean 
± SEM (n=6). The statistical significance p<0.05 is in comparison with a) control, b) 
GSNO, c) SNAP, d) GSH and e) AG. Note that the comparisons were made between 

































Fig. 4.7: Standard straight line graph of hydroxyproline assay. X-axis corresponds 
to the hydroxyproline concentrations and the Y-axis corresponds to optical density 


































































































































ig. 4.8: Hydroxyproline concentration of scars treated with GSNO, SNAP, GSH and AG. Results are mean ±
EM (n=6). The statistical significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e)
G. Note that the comparisons were made between the groups of the same day and error bars correspond to SEM. 
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 4.4 Tissue protein content 
The protein content of each tissue was measured before conducting MMP activity 
assay, total nitrite and total glutathione content in the scars (Fig. 4.9). The values 
obtained by these assays are normalized to the protein content of the corresponding 
sample. Similarly the plasma nitrite and nitrate is also normalized to the protein 
content. The protein concentration of the scars varied between 2-3 mg/ml whereas 





























Fig. 4.9: Standard straight line graph for protein estimation. This graph is used in 
determining protein concentration in scar tissues. Each point represents an average 
of two readings at 590 nm absorbance. X-axis represents protein concentrations and 




4.5 Gelatinase Activity 
Gelatinases are expressed in high concentrations during wound healing. The 
gelatinase (A&B) activity was determined in the scars of animals treated with NO 
donors and inhibitor. The Chemicon Gelatinase activity kit provides an accurate 
and repeatable procedure to determine the activity.  
4.5.1 Effects of GSNO, SNAP and GSH on wound gelatinase activity 
The gelatinase activity in the control scars was 10.38 ± 3.07, units/mg( u/mg) during 
the third day, 80.55 ±9.57 u/mg on the fifth day, 20.12 ± 4.99 u/mg on the 7th day and 
32.63 ± 3.44 on the 10th post-wounding day (Table 4.4, Fig. 4.10). This suggests that 
there is a very short period (five days) of increased activity of the gelatinases 
following injury. This is consistent with the previously reported studies by Chia 
Soon (2000) that the action of gelatinase is transient. The activity of the GSNO 
treated scars was similar to that of the control scars. At the tenth post-wounding 
day gelatinase activity in the GSNO treated group is significantly lower than the 
control scars (p <0.05). SNAP had lower activity during the 5th post-wounding day 
compared to control and GSNO (p<0.05). On the 10th post-wounding day SNAP 
treated scars had lower gelatinase activity compared to control group. Gelatinase 
activity was decreased in GSH treated scars on the 5th and the tenth day compared 
to control and was lower than the GSNO group on the 5th post-wounding day 
(p<0.05). 
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4.5.2 Effects of AG on wound gelatinase activity 
AG treatment increased the scar gelatinase activity significantly high on the third 
post-wounding day, after which the activity decreased. The activity in the AG 
treated scars was significantly higher than the control, GSNO, SNAP and GSH 
treated scars on the third post-wounding day. The activity significantly decreased by 
the 5th post-wounding day compared to control, GSNO, SNAP and GSH. The 
activity of the AG treated scars on the 7th and 10th post-wounding days is not 
significantly different compared to the control group.  
 
Group Day 3 Day 5 Day 7 Day 10 
Control 10.38 ± 3.07 80.55 ±9.57  20.12 ± 4.99 32.63 ±3.44 
GSNO 23.33 ±4.15 88.70 ± 9.3 c,d,e 7.23 ±3.01 18.14 ±3.25 a 
SNAP 14.7 ± 4.27 10.84 ±2.24 a 17.34 ± 4.5 13.9 ±4.94 a 
GSH 22.82 ±5.29 25.7 ±3.05 a 18.15 ± 5.69 16.12 ± 2.29 a 
AG 44.49 ± 11.85 a,b,c,d 26.4 ±9.14 a 16.84 ±1.6 27.7 ± 8.21  
 
 
Table 4.4: Gelatinase activity of the scars. The gelatinase activity (u/mg protein) of 
the scars treated with GSNO, SNAP, AG and GSH at 3, 5, 7 and 10 days post-
wounding are shown in this table. Results are mean ± SEM (n=6). The statistical 
significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH 






















































































































































a a a a 
ig. 4.10: Gelatinase activity in the scars of animals treated with GSNO, SNAP, AG and GSH. Results are mean ± SEM
n=6). The statistical significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. Note
hat the comparisons were made between the groups of the same day and error bars correspond to SEM 
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4.6 Nitrite and nitrate (total nitrite) content 
The effects of NO donor and inhibitor on the scar and plasma nitrite and nitrate 
were measured by the Griess method.  
4.6.1 Scar nitrite and nitrate content 
The effect of the NO donors and inhibitor scar nitrite content was measured at 3, 5, 
7 and 10 days in all the groups.  
4.6.1.1 Effects of GSNO, SNAP and GSH on scar nitrite content 
The total nitrite was measured in the scars of animals treated with the above-
mentioned drugs. The nitrate in each scar was further reduced to nitrite by 
aspergillus reductase and the total nitrite was measured at 545nm (Fig. 4.11). The 
nitrite content in the control scars on the 3rd, 5th, 7th and 10th post-wounding days 
were 28.60 ± 13.71, 30.61 ± 13.63, 24.08 ± 7.74 and 38.81 ± 3.37  µM/mg respectively 
(Fig. 4.12). The previous reports regarding the time course variation of NO in 
wound healing suggest that there is a peak by the 3rd post-operative day and later 
the nitrite and nitrate decreases (Richard H. Lee, 2001). The variation in 
observation could be due to the change in the tissue model. The previous report was 
on the subcutaneous sponges placed in the scar area, whereas in this report the 
nitrite and nitrate are directly measured form the scar homogenate. Nitrite and 
nitrate being terminal metabolic byproducts of nitric oxide tend to accumulate in 
the tissue. By three days, nitrite content of the GSNO treated scars was significantly 
higher than the control SNAP, GSH and AG treated group (Table 4.5). The rest of 
the time points showed no difference in nitrite and nitrate levels.  SNAP showed no 
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significant change in scar nitrite content. The GSH group had no significant changes 
on the scar nitrite and nitrate content. 
4.6.1.2 Effects of AG on scar nitrite content 
The scar nitrite content of AG treated scars showed a trend towards decreased 
values. No statistical significance was seen as the variation in each group is very 
high. AG scars had significantly lower nitrite content on the 3rd post-wounding day 
compared to GSNO group. On the 5th day AG group nitrite values were significantly 
lower than the SNAP group (p<0.05). By the tenth post-wounding day the scar 
nitrite content was lower than the control and GSNO treated group.   
 
Group Day 3 Day 5 Day 7 Day 10 
Control 28.6±13.71 30.61±13.63 24.08±7.74 38.81±3.37 
GSNO 63.88±20.77 a,c,d,e 32.9±3.60 24.53±1.24 42.31±13.29 
SNAP 23.71±3.47 47.61±8.74 36.99±6.3 33.56±8.12 
GSH 11.70±1.88 20.97±7.88 21.38±3.72 19.38±1.33 
AG 7.68±1.28  11.50±5.67 c 26.45±15.09 12.14±2.14 a,b 
 
 
Table 4.5: Nitrite and Nitrate content of the scars. The total nitrite content of the 
scars treated with GSNO, SNAP, AG and GSH at 3, 5, 7 and 10 days post-wounding 
are shown in this table. Results are mean ± SEM (n=6). The statistical significance 
p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. 







 4.6.2 Plasma nitrite content 
 
Following the administration of NO donors and iNOS inhibitors, the changes in the 
plasma nitrite and nitrate were monitored. The increase in the plasma nitrite was 
taken as a reference for the harvesting of the tissues. Therefore the time at which 
the plasma nitrite and nitrate increase was noted and the scar specimens were 
harvested accordingly to observe the maximum response following treatment. This 
was done by reducing the nitrate to nitrite by aspergillus reductase enzyme and 
adding the Griess reagents (Section 3.2.6.1).   
4.6.2.1 Effects of GSNO and SNAP on the plasma nitrite  
The plasma nitrite was measured at 1, 3 and 5 hours following administration of 
GSNO and SNAP. The plasma nitrite at various hours was compared with control 
group. The mean plasma nitrite of all the control animals was 0.498 ±0.084 (Fig. 
4.13).  GSNO increased plasma nitrite by 3 hours after which it returned to normal 
(table 4.6).  SNAP significantly increased the plasma nitrite content at 3rd and 5th 
hour after injection. The administration of GSNO in our study was much higher 
compared to the previous reports (Stefania, 1999). SNAP on the other hand 





4.6.2.2 Effects of AG on plasma nitrite  
The plasma nitrite concentrations did not vary following AG administration. 
Previous studies have suggested higher dose administration of AG (Michael 
Schaffer, 1999). In our study, high doses were administered initially but the effects 
of higher doses of AG are detrimental as it causes hypertension. 
 
 
Group 1 hour 3 hours 5 hours 
GSNO 0.428±0.02 0.679±0.04 a,d 0.496±0.057 
SNAP 0.815±0.2 a,b,d 1.44±0.281a,b,d 0.62±0.068a,b,d 
AG 0.316±0.071 0.372±0.04 0.39±0.052 
 
 
Table 4.6: Nitrite and Nitrate content of the plasma. The total nitrite content of the 
plasma treated with GSNO, SNAP and AG at 1, 3 and 5 hours after the initial 
injection of the drug are shown in this table. Results are mean ± SEM (n=6). The 
statistical significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, 
d) AG. Note that the comparisons were made between the groups of the same day 






































Fig 4.11: Standard straight line graph of nitrite concentrations. The standards are 
prepared by known concentrations of sodium nitrite ranging from 2.5– 15 µM/ml. 
The concentrations are measured at an absorbance of 545nm. Each point represents 











































































































































































































Fig. 4.12: Nitrite content of scar samples obtained at 3, 5, 7 and 10 days post-wounding. Results are mean ± SEM (n=6).
The statistical significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. Note that the




























































































































: Plasma nitrite concentration following the administration of GSNO, SNAP and AG (n=6). The plasma samples
ken 1, 3 and 5 hours after the administration of the drugs. Error bars correspond to SEM and the statistical
nce p<0.05 is in comparison with a) control, b) GSNO, c) SNAP and d) AG. Note that the comparisons were
tween the groups of the same day and error bars correspond to SEM. 
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4.7 Glutathione content 
 
The drugs administered interact with the tissue glutathione. The cellular glutathione 
acts as a major sink for most of the nitrites and nitrates formed in the cell. 
Therefore the variation in the levels of glutathione in the scar was measured. Scar 
GSSG levels were measured using the Cayman Glutathione assay kit. The results 
were compared with the standard straight line obtained by known concentrations of 
GSSG standards (Fig. 4.14). The GSSG content of each scar was normalized to the 
protein content of the scar.  
4.7.1 Effects of GSNO, SNAP and GSH on scar glutathione content 
The glutathione content of the control scars was 19.61±4.17,  18.34±1.81,  16.32±2.8 and  
27.48±3.59 µM/mg protein on the 3rd, 5th, 7th and 10th post-wounding day (Table 4.7, 
Fig. 4.15). Therefore the GSSG content was constantly maintained throughout these 
time points. The GSSG content of GSNO group decreased significantly on the 10th 
post-wounding day compared to control (p<0.05). SNAP treated scars had 
significantly lower GSSG levels on 3rd, 5th, 7th and 10th compared to control, GSNO 
and GSH groups. GSH treated group had significantly higher GSSG than the 
GSNO group on the 7th and 10th post-wounding day. 
4.7.2 Effects of AG on scar glutathione content 
Scar GSSG content in the AG treated animals were relatively lower compared to the 
Control and GSNO group on the 3rd and 5th day post-wounding (p<0.05). The SNAP 
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treated group had significantly lower GSSG content than the AG group at 3rd, 5th, 
7th and 10th post-wounding days.          
 
Group Day 3 Day 5 Day 7 Day 10 
Control 19.61±4.17 18.34±1.81 16.32±2.8 27.48±3.59 
GSNO 17.90±2.19 c 21.57±4.92 c,d,e 11.84±1.51 17.17±2.95 b 
SNAP 3.49±0.647 a 2.16±0.862 a 2.86±0.726 a,b 3.88±1.14 a 
GSH 14.2±1.05 b 13.15±0.938 b 22.22±6.09 b 26.69±3.07 b 
AG 11.01±1.48 a,b 10.77±1.74 b 13.94±0.505 b 21.26±1.5 b 
 
Table 4.7: Glutathione (GSSG) content of the scars. The glutathione content of the 
scars treated with GSNO, SNAP, AG and GSH at 3, 5, 7 and 10 days post-wounding 
are shown in this table. Results are mean ± SEM (n=6). The statistical significance 
p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. 














































Fig 4.14: Standard straight line graph of glutathione determined by Cayman 
Glutathione assay kit. The graph represents the oxidized form of glutathione 
(GSSG). The readings are an average of two independent samples. The 
concentration of glutathione is read as an absorbance at 490 nm. X-axis represents 













































































































































































































































5: Total glutathione concentration of scars at 3, 5, 7 and 10 days post-wounding. Results are mean ± SEM (n=6).
tistical significance p<0.05 is in comparison with a) control, b) GSNO, c) SNAP, d) GSH and e) AG. Note that the
isons were made between the groups of the same day and error bars correspond to SEM. 
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4.8 Peritoneal macrophage flow cytometry 
Nitric oxide is involved in the modulation of inflammatory responses, immune 
regulation and host defense. Therefore it is essential to examine the effect of NO 
modulating drugs on immune cells. As the NO donors and inhibitors were 
administered intra-peritoneally, the effects of these drugs on the expression of 
surface markers of peritoneal immune cells were studied.  The MHC Class I, Class 
II and ICAM-1 markers are expressed on most of the peritoneal immune cells. To 
study the effect of these cells, single colour flow cytometry was conducted on the 
cellular extract obtained from the peritoneal lavage. The results obtained by flow 
cytometry are analysed using WinMDI version 2.8. Mean percentage of the 
population of the cells that stained positive was compared with the IgG isotype 
control (Fig. 4.16). All the peritoneal lavages were carried out in the rats after 3 
hours of drug administration, which corresponds to the time point of maximum 



































Fig. 4.16: Dot-Plot representation obtained by plotting the A) unstained peritoneal 
cells (negative control) and B) IgG isotype control. The analysis is done by plotting 
the log of FITC fluorescence in the X-axis and PE in the Y-axis. The gating is done 
based on the IgG readings.  
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4.8.1 Effects of GSNO, SNAP and AG on MHC Class I surface marker  
MHC Class I marker is expressed by most of the nucleated cells. Expression of 
MHC class I is important in the recognition of self and non-self antigens.  
4.8.1.1 Effects of GSNO and SNAP on MHC Class I marker 
The expression of Class I marker was seen in 26.74 % of the peritoneal cells in the 
control group (Fig 4.17). The animals treated with GSNO had 22.35 % positive 
population and that of SNAP was 23.68 %. Neither GSNO nor SNAP showed any 
significant effect on the expression of Class I surface marker.   
4.8.1.2 Effects of AG on MHC Class I marker 
The expression of Class I surface marker was seen on 16.56 % of peritoneal cells in 
the AG treated group. Though the AG group had lower percentage of cells staining 
positive, no statistical significance were observed. Aminoguanidine has previously 
been studied to inhibit Class I marker in preventing pot-transfusion development of 


























































































4.17: Expression of MHC Class I surface markers on the peritoneal cells. The mean percentage of cells
ing positive for the Class I surface marker are represented in each group (n=6). Error bars correspond to
. Y-axis represents the percentage of positively stained population. 
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4.8.2 Effects of GSNO, SNAP and AG on MHC Class II surface marker 
The effect of NO donors on the expression of MHC Class II antigens  was 
investigated in the peritoneal cells. Class II markers are expressed on the surface of 
macrophages, B-cells and dendritic cells. Expression of Class II molecules indicates 
the immune cell activation.  
4.8.2.1 Effects of GSNO and SNAP on MHC Class II marker 
There was significant increase in the peritoneal cells staining positive in animals 
treated with SNAP (p<0.05). GSNO treated group showed no significant changes 
compared to the control group (Fig. 4.18). Our observations are similar to the 
previous reports, where GSNO does not affect rat splenocyte MHC Class II 
expression (Badovinac V, 2000). The effects of SNAP in our study are in contrary to 
the previous observations where SNAP administration led to decrease in expression 
of Class II surface marker (Lu L, 1996).  
4.8.2.2 Effects of AG on Class II marker 
The expression of Class II surface marker in the AG treated group was significantly 
lower than that of the SNAP treated animals. In previous studies, expression of 
MHC Class II surface marker was reduced by AG and N-methyl-L-arginine (Ross 
R, 1998). This is similar to our observation that administration of AG decreases 


























































.18: Expression of MHC Class II surface markers on the peritoneal cells. The mean percentage of cells staining 
ve for the Class II surface marker are represented in each group (n=6). Error bars correspond to SEM. Y-axis 
sents the percentage of positively stained population. a, b and c are the statistical significance (p<0.05) compared 
trol, GSNO and AG respectively. 
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4.8.3 Effects of GSNO, SNAP and AG on ICAM-1 surface marker 
The expression of ICAM-1 (CD54), which plays a significant role in the adhesion of 
lymphocytes to endothelial cells and regulates immune cell function in the 
peritoneum (Patarroyo M, 1994). The effect of NO donors and inhibitors was 
studied on the expression of ICAM-1 markers on the immune cells of the 
peritoneum.   
4.8.3.1 Effects of GSNO and SNAP on ICAM-1 surface marker 
The ICAM-1 was expressed in 33.1 % of the peritoneal cells in the control group. 
The GSNO group had 7.47 % positive staining cells and that of SNAP group was 
4.28% (Fig. 4.19). Previous studies have shown that SNAP attenuates the 
upregulation of ICAM-1 expression in rat endothelial cells (Christian Kupatt, 1997) 
and GSNO decreases the expression of ICAM-1 in human skin.  There was 
significant decrease in the expression of ICAM-1 markers in the GSNO and SNAP 
treated group. 
4.8.3.2 Effects of AG on ICAM-1 expression  
AG treated animals had 8.02% positive cells for ICAM-1. This was significantly 
lower compared to the control group (p<0.05). NO inhibitors are known to increase 
leukocyte adhesion (Christian Kupatt, 1997 & Benedetta Bussolati, 2002). Following 
AG administration, ICAM-1 expression decreased in our experimental setup. In a 
separate study conducted by Seijiro Kado et al (2001), it was shown that 














































ig. 4.19: Expression of ICAM-1 surface markers on the peritoneal cells. The mean percentage of cells
aining positive for the ICAM-1 surface marker are represented in each group (n=6). Error bars correspond

























4.9 Histology  
Gross examination of the scars did not show any significant changes under light 
microscopy (Fig. 4.20). Histologic examination of the scars from one or more animal 
from each group was done at different time points. The scar tissue consisted of 
fibroblasts and dense collagen bundles. Blood vessels were dilated, with margination 
and extravasation of leukocytes. The surface of the wound was covered with a crust 
composed of desiccated, degenerate leukocytes, fibrin and proteinacious debris. 
Subjacent to this was a matrix with edematous connective tissue, fibroblasts, fibrin, 
proteinacious debris and leukocytes. Neovascular networks and proliferating 
fibroblasts created a granulation tissue bed. Epidermis at the cut edges became 
hyperplastic. Migration of the epidermal tongue undermined the scab, which 
consisted of a desiccated surface crust with subjacent layer of intermediate scab 
matrix consisting of proteinaceous debris, fluid, leukocytes, fibrin and fibroblasts 
but no recognizable capillaries. Migration of the epidermis continued until the 
defect was bridged. Granulation tissue continued to proliferate upwardly until the 
wound bed was filled, and then began its maturation into fibrous connective tissue 
of the eventual scar. Fibroblasts began forming rows parallel to the surface to the 
wound. After the defect was bridged and filled in capillaries began to recede. 










Fig. 4.20: Haemotoxylin and Eosin staining of normal skin and scars. A) normal skin (20X), B) scar (20X), 
C) normal scar (10X), D) Scar with fibrous tissue (20X), E) close view (40X) of fibrous tissue, dense 
fibroblasts are seen (arrow), F) close view of a capillary in the scar tissue (40X). 
   
   
A B C 
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4.9.1 Immunohistochemistry 
Immunohistochemistry of MMP2 and MMP9 were done in animals 
treated with GSNO and AG. eNOS and iNOS isoenzymes were localized 
using monoclonal antibodies. The slides were compared with negative 








Fig. 4.21: Negative controls used in the staining. Scar tissues  
(A&B) without the primary antibody serve as negative control. 
This picture shows the close view of the dermis with dense 
fibroblasts (40X). 
4.9.1.1 Immunohistochemistry of MMP2 & MMP9 
In order to evaluate the effects of GSNO and AG on the protein expression of 
Gelatinases, localization was done by immunohistochemistry on the GSNO treated 
scars. The scoring method as previously described by Moochhala S (1996) was 
adopted in this study. The results were analyzed by Kruskal-wallis test for multiple 
comparisons of non-parametric data. The median score of staining of each group 
was compared. 
 
4.9.1.1.1 Effects of GSNO on MMP2 expression in scars 
MMP2 immunostaining was done on skin sections at 3, 5, 7 and 10 days in the 
control and GSNO treated scars (Fig. 4.22). The expression of gelatinase A was seen 
in most of the cells in the dermis and the epidermis. In the control scars, expression 
of MMP2 was significantly higher at 3 and 5 days post-wounding the median score 
was 4, following which it decreases by day 7. By day 10 it reaches a median score of 
1. Similarly the Gelatinase A expression in GSNO treated scars was lower in the 
treated scars. Only on the seventh post-operative day the GSNO treated scar 
showed marginally higher expression of MMP2 than the control scars. But there 
was no statistical significance seen in these various scars at 3, 5, 7 and 10 days post-
wounding.  Note that the expression of the MMP2 is seen in fibroblasts and 
epithelial cells. No changes are see in the inflammatory infiltrate in the GSNO 
treated and control animals. 
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4.9.1.1.2 Effects of AG on MMP2 expression in scars 
The expression of Gelatinase A was seen in most of the cells in the dermis and the 
epidermis. There was no significant difference in the scoring of the scars stained for 
gelatinase-A. No significant histological changes were observed in the scars treated 






















Fig. 4.22: Immunohistochemistry of MMP2 enzymes in scars treated with A) Saline (control) B) GSNO and C) AG. The expression 
of MMP2 is observed in fibroblasts (arrow) inflammatory infiltrates (dotted arrow).  All the microscopic observations were done at 
20X magnification. 
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4.9.1.1.3 Effects of GSNO on MMP9 expression in scars  
Immunohistochemistry of MMP9 (Fig. 4.23) in the scars at various time points 
revealed that there is no significant change in the normal samples at all time points. 
The expression decreases by 5th post-operative day and again returns to levels 
similar to the 3rd day. Treatment with GSNO increases the protein expression 
significantly on day 5 compared to the normal, and the rest of the time points there 
is no significant difference. The major effect of MMP9 in wound healing is mainly 
on the epithelialisation, The immunostaining of Gelatinase B shows increased 
expression by fibroblasts and inflammatory cells. 
 
4.9.1.1.4 Effects of AG on MMP9 expression of scars 
Immunostaining of gelatinase-B on AG treated scars revealed no significant 
difference in the protein expression. The dermal fibroblasts and infiltrated 
polymorphs showed positive staining of this antibody. Scoring of these sections 












Fig. 4.23: Immunohistochemistry of MMP9 enzymes in scars treated with A) Saline (20X) B) GSNO (20X)and C) AG (10X). 
The expression of MMP9 is observed in fibroblasts (arrow) inflammatory infiltrates (dotted arrow).   
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4.9.1.2 Immunohistochemistry of NOS isoenzymes 
 
4.9.1.2.1 Effects of GSNO on eNOS expression in scars 
All blood vessel endothelium within wound beds stained strongly positive for eNOS, 
illustrating the location and density of capillaries. eNOS also stained positive for the 
epidermal cells more towards the upper layers. Non-wounded skin also showed 
positive eNOS staining. Immunostaining (Fig. 4.24) was done on the scars at 
different time points but no significant difference was observed between the groups. 
There was no noticeable effect of GSNO on the expression of eNOS. The drug does 
not seem to have any effect on the expression of eNOS isoenzyme. The staining of 
eNOS revealed that the enzyme was also present in normal uninjured skin. 
 
4.9.1.2.2 Effects of AG on eNOS expression in scars 
Immunostaining of AG did not have histologically visible effect on the eNOS 
expression. The protein was expressed in the epidermal layer and few dermal 













Fig. 4.24: Immunohistochemistry of eNOS enzymes in scars treated with A) Saline (control) B) GSNO and C) AG. The 
expression of eNOS is observed in keratinocytes, fibroblasts (arrow) and inflammatory infiltrates (dotted arrow).  All the 




4.9.1.2.3 Effects of GSNO on iNOS expression in scars 
Care was taken to clearly examine the slides and to score them. Positive staining of 
iNOS was not significant and was occasionally seen in a few sections (Fig. 4.25). As 
the staining was insignificant, scoring could not be done. Most of the specimens even 
did not have positive staining. The iNOS staining is very much limited to cells such 
as the polymorphs and macrophage like cells in the scar environment.  
 
4.9.1.2.4 Effects of AG on iNOS expression in scars 
No significant difference was seen between treatment groups in 
immunohistochemical staining pattern for iNOS isoform.  AG is a competitive 
inhibitor of NOS that competes with L-arginine. Therefore it will not affect the 
expression of the enzyme. The expression of iNOS enzyme was not observed in most 
of the control, GSNO or AG treated scars. The effects of inhibition are better 













   
Fig. 4.25: Immunohistochemistry of iNOS enzymes in scars treated with A) Saline (control) B) GSNO and C) AG. The 
expression of iNOS is observed in inflammatory infiltrates (arrow).  All the microscopic observations were done at 20X 
magnification 

















5.1  Experimental design 
 
Nitric oxide and glutathione are highly reactive molecules that are 
known to regulate important cellular functions. In this study we have 
examined the effects of GSNO, a nitrosothiol which is a well-known NO 
donor. This compound also produces glutathione upon cleavage. The 
effects of this drug were compared to another nitrosothiol NO donor, 
SNAP and glutathione. An iNOS specific inhibitor, AG was adopted to 
study the effects of NO inhibition on wound healing. 
5.1.1 Rate of wound contraction 
Wound contraction represents a complex and well co-ordinated event, 
which involves processes such as migration of keratinocytes and 
fibroblasts, deposition of matrix tissue, interaction of cells and cytokines 
leading to proper healing. A square wound model was adopted to 
compare the effects of a NO donor, GSNO and an iNOS specific 
inhibitor, AG on wound contraction. The results are interpreted as rate 
of wound contraction.  
5.1.2 Tensile strength 
Biomechanical strength is a key factor in determining the final outcome 
of healing. One of the most crucial phases in wound healing is the 
progressive increase in biomechanical strength of the tissue resulting 
from the formation and turnover of granulation tissue. Although, the rat 
represents one of the most common models used in the study of dermal 
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wound healing, no detailed study has been performed to correlate the 
biomechanical and biochemical changes occurring in the rat dermis 
during normal healing. Standardized protocols were developed for use in 
a detailed investigation into the biomechanical and biochemical 
properties of a dermal wound healing model in the rat. The methodology 
described allowed for the simultaneous and reproducible measurement 
of tensile strength and collagen content.   
5.1.3 Collagen content 
In the present study we have examined the effects of GSNO on the 
collagen content in a rat wound model. In order to attribute the effects of 
GSNO to it’s NO or GSH components, we have used SNAP and GSH to 
serve as controls.   
5.1.4 Gelatinase activity 
Using Fluorescent substrate degradation method and 
immunohistochemistry we studied the effect of NO donors on wound 
gelatinase expression.  During wound healing in rat skin, six MMP genes 
are expressed  (ST1, ST3, GelA, GelB, Col3, MT1-MMP). Among these 
six MMP genes ST1, GelB, and Col3 are mainly expressed between days 
1 and 5 after cutaneous incision, while the three others, MT1-MMP, 
GelA, and ST3, continued to be expressed at high levels until day 7. High 
levels of GelA were observed in the wound stroma, particularly on day 5 
after cutaneous incision when both the MT1-MMP and GelA RNAs 
attained their highest expression levels. This observation suggests that 
GelA activated by MT1-MMP contributes to the remodeling processes 
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implicated in the restoration of connective tissue. In this study, the 
expression patterns of gelatinase A and gelatinase B were investigated in 
rodent cutaneous wound samples. Collagen substrate degradation is a 
relevant method for investigating the activity of MMPs and, since most 
MMPs degrade their specific substrates. Due to the general lack of 
immunohistochemical antibodies detecting only the activated MMP 
form, a combination of activity and immunolocalization would suggest 
the differential effect of the NO donors and inhibitors on the level of 
activity of the enzyme. 
5.1.5 Glutathione content 
The scar wound glutathione content was measured by the Cayman’s 
glutathione assay kit. In this method the sulfhydryl group of GSH reacts 
with DTNB (5,5’-dithiobis-2-nitrobenzoic acid, Ellman’s reagent) and 
produces a yellow colored 5-thio-2-nitrobenzoic acid (TNB). The mixed 
disulfide, GSTNB (between GSH and TNB) that is concomitantly 
produced, is reduced by glutathione reductase to recycle the GSH and 
produce more TNB. The rate of TNB production is directly proportional 
to this recycling reaction, which is in turn directly proportional to the 
concentration of GSH in the sample. Measurement of the absorbance of 
TNB at 405 or 414 nm provides an accurate estimation of GSH in the 
sample. The administration of GSNO and SNAP had varied responses on 




5.2 Effects of NO donors and inhibitor on wound healing 
 
5.2.1 Effects of GSNO on wound healing 
The control wounds healed between 12-14 days post wounding. During 
the first two days there was an increase in the wound area as a result of 
traction of the surrounding tissue and loose attachment to the underlying 
connective tissue. Administration of GSNO improves the rate of wound 
contraction by 46% compared to controls (saline treated animals). This 
implies GSNO improves keratinocyte and fibroblast proliferation and 
migration and enhances collagen deposition, which form the center stage 
of wound healing. Early wound closure decreases the possibilities of 
wound infection and other related complications such as development of 
large scars due to delayed healing. In vitro studies of the effects of GSNO 
on keratinocytes have shown that it promotes proliferation and 
differentiation of the cells (Frank S, 1999). Previous studies pertaining to 
NO releasing drugs were either only on the collagen content or strength 
of the scar (Witte M.B, 2002; Shi H. P, 2002) whereas we have clearly 
studied the effects on rate of wound contraction as well. The fact that 
GSNO improves the load to failure and stiffness shows that it enhances 
the total wound strength, thus giving a stronger and stiffer scar. To 
measure the biomechanical properties of skin a standard protocol 
previously established by Paul RG et al (1997) has been adopted. The 
improvement in the biomechanical properties and rate of wound 
contraction indicate that GSNO not only enhances the speed of healing 
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but also the quality of the wound. This is the first report where the 
complete outcome of healing in the form of wound contraction and 
strength of the scar following the administration of a NO donor has been 
studied. To completely understand the underlying mechanism of 
improvement in wound healing we quantified the hydroxyproline 
content, which is a direct measure of the collagen content.  Our 
experiments show that treatment of wounds with GSNO resulted in 
increased collagen content. The control scars exhibit increased deposition 
of collagen by the fifth day and at later time points the collagen 
deposition is lower. The collagen deposition in the GSNO treated scars 
followed the same pattern as in control scars, i.e. it increases by day 5 
and decreases by day 10, but was significantly higher. This implies that 
GSNO facilitates physiological reparative tissue deposition. 
The exact mechanism by which NO enhances collagen deposition is not 
known. Witte M. B. et al (1996) demonstrated that NO enhances collagen 
synthesis, most likely at a posttranscriptional level. As wound healing 
progresses, increased arginase activity produces an environment 
favorable for fibroblast replication and collagen production (Witte M. B, 
2002). Contrary to our findings Arti Shukla et al (1999) have reported a 
decrease in wound collagen synthesis following sodium nitroprusside 
(SNP) administration. The release of NO by SNP is negligible. It has been 
shown by David A. Wink et al (1996) that, compared to many NO donors 
such as GSNO and SNAP, the release of NO by SNP is insignificant. 
Therefore the decreased wound collagen deposition following SNP could 
be a result of the release of more cytotoxic byproducts such as cyanide, 
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which inhibits iron moiety. Moreover the topical application of SNP 
results in the release of small quantities of NO, which would diffuse into 
the external atmosphere than entering the wound environment. The 
present experiments demonstrate that administration of GSNO increases 
collagen deposition. The effects of GSNO were studied on the protein 
expression of gelatinases. Immunohistochemical localization revealed 
that there was no significant change following administration of GSNO 
and AG. This may be because the drug might act on the activation 
mechanisms of the extracellular enzymes. We clearly demonstrated the 
differences in the GSNO treated and the rest of the groups such as 
SNAP, AG and GSH groups. MMP activity in wound healing is vital for 
most of the physiological processes, such as epithelialisation, 
debridement, infiltration of inflammatory and parenchymal cells 
(Velimatti kahari, 1997). The above-mentioned processes occur mainly 
during the phase of inflammation (up-to 3 days) and phase of ECM 
deposition and re-epithelialisation (up-to 10 days). The activity of MMP 
is not affected in the initial phase. This indicates that GSNO does not 
affect the vital physiological processes such as debridement, keratinocyte 
migration and dissolution of clot, which are chiefly controlled by MMP. 
Though it has been found that GSNO inhibits MMP activity in platelets 
and in turn inhibits platelet aggregation the effect is not to such an extent 
to affect healing. Debridement, inflammation and epithelialisation were 




In our study we have observed an increase in the collagen content 
without any interference of MMP activity. Alteration of this vital process 
would result in aberrant healing. Any wound enhancing agent 
necessarily has to have no effect on these enzymes. Certain reports 
regarding inhibition of MMP activity by NO have been carried out in an 
in-vitro set-up (Marek W. Radomski, 1992). The MMP inhibitory effect 
in an in vivo model may not be as pronounced as in vitro as the NO 
donor compounds undergo various intermediary metabolism pathways. 
Optimal wound healing involves appropriate deposition of collagen, 
improved activity of gelatinases and regaining of original strength. This 
when compared to GSNO in our study revealed that there was no 
inhibition of MMP activity. There are other similar studies especially 
regarding the vascular endothelium that inhibition of MMP release by 
NO is one of the pathways in preventing the occurrence of 
atherosclerosis. Our report suggests that enhanced collagen deposition, 
uninhibited MMP activity and thiol status favor enhanced wound 
healing. The mechanisms of MMP regulation by various RSNO’s are yet 
to be studied in detail. The facilitatory and the regulatory effects of 
GSNO on wound healing following its biotransformation in the wound 
environment may provide possible targets for further research in the 
enhancement of wound healing. The drugs administered interact with the 
tissue glutathione. The cellular glutathione acts as a major sink for most 
of the nitrites and nitrates formed in the cell (for details see section 5.6). 
Therefore the variation in the levels of glutathione in the scar was 
measured. The control scars had similar GSSG at all time points of 
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wound healing, with a significant increase by day 10. This could be 
mainly due to accumulation of the anti-oxidants by the time all the free 
radicals are neutralized. Similar results are also seen in the GSH treated 
scars. GSNO treated scars had comparable GSSG levels with the control 
scars. The total nitrite was measured in the scars of animals treated with 
the above-mentioned drugs. The nitrate was further reduced to nitrite by 
aspergillus reductase and the total nitrite was measured at 540nm. By 
three days, nitrite content of the GSNO treated scars was 55% more than 
the control group. The rest of the time points showed no difference in 
nitrite and nitrate levels.  SNAP showed no significant change in scar 
nitrite content. The variation in plasma nitrite was monitored following 
the administration of the NO donors GSNO and SNAP. This is important 
as it gives a clear picture of the systemic nitrite variation in the body 
following NO donor administration. Our results show that GSNO 
increases nitrite in the plasma by 3 hours of administration and then 
returns to control levels by the fifth hour. 
 
5.2.2 Effects of SNAP on wound healing 
The rats were treated with equimolar doses of SNAP compared to 
nitrosoglutathione. The effects were examined on the biomechanical 
properties, collagen content, gelatinase activity and the glutathione levels. 
Load to failure and stiffness showed no significant difference compared 
to controls. Collagen content was significantly lower than the control and 
GSNO groups on the 5th post-wounding day (p<0.05) but by the tenth 
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post-wounding day no significant differences were observed. This 
compound has been shown to restore the collagen secretion in iNOS 
knock-out fibroblasts. But in an intact animal where SNAP undergoes 
intermediary metabolism and constant interaction with other cells and 
may exert its action in a manner different from that in an in vitro set up. 
through other pathways. The gelatinase activity was  lower in the SNAP 
treated scars. In a separate set of experiments, Maria Angeles Martinez 
et al (2001) have demonstrated that SNAP inhibited MMP-2 activity 
through the activation of cGMP in platelets. This inturn inhibits platetlet 
aggregation. Therefore MMP-2 is an important enzyme that promotes 
fibrinogen stimulated platelet aggregation and NO from SNAP inhibits 
this vital physiological process. Tatsuya Okamoto et al (2002) have 
demonstrated that SNAP suppress MMP-9 induction by preventing NF-
B activation through the inhibition of nuclear translocation and/or DNA 
binding. Though the gelatinase activity decreased there was no changes 
in the collagen content. The SNAP treated scars had significantly lower 
levels of glutathione. It was found that SNAP lowers activity of 
glutathione reductase which in turn leads to decreased GSSG levels 
(Tsuneko Fujii, 2000; Kang KW, 2002). In wound healing it becomes 
more complicated to clearly infer the effect of SNAP on tissue oxidative 
status as it involves interaction of parenchymal and immune cellswhich 
are rich in anti-oxidants. In this study no significant change in scar 
nitrite content was observed following SNAP administration.  
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5.2.3 Effects of GSH on wound healing 
 
The biomechanical testing of the GSH treated scars revealed lower 
stiffness than the control, SNAP and GSNO groups at the tenth day. The 
collagen content was lower by 76% on the 5th post-wounding day 
compared to the control group (p<0.05) and by the 10th day, it reached 
control levels. Collagen synthesis has been shown to improve following 
administration of certain anti-oxidant precursors such as VitC, 
Rexofelast (VitE related compound). GSH has been found to inhibit 
collagen synthesis in certain tissues such as the airway epithelium, (Hui 
Jung Kim, 2002) hepatocytes (Shanthi Wasser, 2001) and mesangial cells 
(Mark A. Catherwood, 2002). Thus the effect of GSNO depends on the 
tissue. Suresh C. Tyagi et al (1993) have also demonstrated that reduced 
GSH reduces the transcription of MMP expression and fibroblast 
proliferation in normal cardiac fibroblasts. Gelatinase activity was 
decreased in GSH treated scars on the 5th and the tenth day compared to 
control and was lower than the GSNO group on the 5th post-wounding 
day (p<0.05). MMP regulation occurs at the level of gene transcription 
and on activation of pro-MMPs. Various stimuli, including growth 
factors, cytokines, chemical agents (phorbol esters), and mechanical 
stress, induce MMP gene expression. The MMP-9 promoter region 
contains nuclear factor-κB, activator protein-1, stimulatory protein-1, 
and phorbol ester–responsive elements (Sato H, 1993). Previous findings 
indicating that nuclear factor-κB and activator protein-1 are redox 
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sensitive offer a potential mechanism by which oxidative stress may 
regulate MMP-9 transcription and activity (Li N, 1999). Another possible 
mechanism for the activation of MMP activity is posttranslational 
modification by ROS. 
5.2.4 Effects of AG on wound healing 
 
The iNOS inhibitor AG did not decrease the rate of wound contraction 
significantly but a trend towards a low rate of wound contraction was 
seen. The results were not statistically significant. As AG is also an 
inhibitor of advanced glycation end products (AGE), collagen cross-
linking is inhibited and this inturn may result in decreased rate of wound 
contraction. But in this study no significant inhibition in the rate of 
wound contraction was noticed.  
Experiments that have been performed in animals, patients and healthy 
volunteers confirm that dietary or intravenous L-arginine 
supplementation enhances both wound breaking strength and collagen 
deposition (Adrian Barbul 1985, Witte MB 2002). In our study the iNOS 
specific inhibitor AG inhibited the deposition of collagen in the scar 
significantly.  
In our experiments we observed that administration of AG increased the 
gelatinase activity in the initial 3 days following healing. Later by the 
fifth day AG lowered the scar gelatinases activity. There was no 
significant difference in the gelatinase activity on the seventh and tenth 
post-wounding days. 
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In our study AG did not alter the antioxidant status in the wound 
environment. The observation of the changes of glutathione depends on 
the tissue that is studied. It is seen that in liver the glutathione levels are 
increased following administration of AG while GSSG levels of kidney 
are reduced (Kurshid Alam, 2001; Dobashi K, 2001). The exact 
mechanisms of glutathione regulation by iNOS inhibitors are not yet 
clearly understood. 
AG administration lowered the scar nitrite content on the 3rd, 5th and 10th 
postwounding day. There was no significant difference on the 7th 
postwounding day. This is contradictory to some previous studies where 
administration of AG in high doses is necessary to achieve reduction in 
scar nitrite content (Michael Schaffer, 1999). 
The administration of AG did not decrease plasma nitrite and nitrate 
content. When higher doses are administered to the rats, immediate 
effects such as altered behavior and restlessness are seen. In a separate 
report Hans Oxlund et al (1996) have observed the decrease in wound 
collagen at a dose of 125mg/kg body weight. As there are varied opinions 
and observations of the effects of AG on plasma nitrite, scar nitrite and 
scar collagen, it is important to measure all the related parameters. 
  
5.3  Summary of discussion 
The present experiments demonstrate that administration of GSNO 
increases collagen deposition. The collagen deposition in the GSNO 
treated scars followed the same pattern as in control scars, i.e. it 
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increases by day 5 and decreases by day 10, but was significantly higher. 
This implies that GSNO facilitates physiological reparative tissue 
deposition. NO has been associated with modulating collagen synthesis in 
the scar (Michael Schaeffer, 1996). Fibroblasts isolated from rat wounds 
were shown to synthesize and release NO in vitro. Moreover, NO 
regulates collagen synthesis by the wound fibroblasts in an autocrine 
fashion (Michael Schaffer, 1997). Inhibition of NO production using S-
methylisothiouronium (S-MITU) was associated with attenuation of 
wound tensile strength and significantly diminished hydroxyproline 
content after wounding (Michael Schaffer, 1999). The increase in 
collagen content may be attributed to increased stimulation of the 
collagen synthesis or increased proliferation of fibroblasts (Ming Du, 
1997; Maria B Witte, 2000). The proliferative effect of GSNO is varied 
and depends on the target cells. For e.g.: Balb/c3T3 (clone A31-1-1) 
fibroblasts (Ming Du, 1997) show increased proliferation whereas NIH 
3T3 cells show induction of apoptosis when exposed to GSNO (Tzyh-
Chyuan Hour, 1999). The exact mechanism by which NO enhances 
collagen deposition is not clearly understood. Interpretation of the 
breakdown of the nitrosothiols becomes more complicated and varied in 
cells and tissues as factors such as the thiols & superoxide, react with 
GSNO and produce many other byproducts (Schmidt K, 1997). To 
understand the breakdown of GSNO, some reports have suggested that a 
different breakdown mechanism of GSNO called GSNO lyase exists in 
the cells (Michael P Gordge, 1998). But, the main effect of GSNO could 
be due to the cellular bio-transformation of this compound, which gives 
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GSSG and other products such as nitrite, nitrate and peroxynitrate.  The 
extracellular breakdown of GSNO and the cellular uptake of the NO 
released by this substance have been linked to the activity of membrane 
protein disulfide isomerase (PDI). This enzyme catalyzes NO release 
from extracellular S-nitrosothiols, which accumulates in the membrane 
and reacts with O2 to produce N2O3. Intracellular thiols may then be 
nitrosated by N2O3 at the membrane-cytosol interface (Niroshan 
Ramachandran, 2001).  Similarly the effect of GSNO on the thiols has 
been studied and found that it has an inhibitory effect on the crystalline 
glutathione reductase (GR), but not on the GR levels of intact cells 
(Becker K, 1995). Therefore, the effects of GSNO are controlled mainly 
by the type of the cells involved in its metabolism and the redox state of 
these cells. GSNO increased plasma nitrite concentration 3 hours 
following administration, which further returned to control levels by 5 
hours.   
Nitrosothiols are found to provide protection against peroxide mediated 
cytotoxicity whereas the other NO donor compounds such as SIN-1 has 
been shown to have no beneficial effects (David A Wink, 1996). The 
administration of GSH itself doesn’t serve any benefit, as the peptide is 
not easily taken up by the cells. It has to be broken into its component 
aminoacids and then taken into the cells. This is followed by intracellular 
synthesis of GSH (Meister A, 1993). Cellular GSH appears to inhibit the 
early signaling events leading to iNOS expression and suggest that the 
control of iNOS induction in hepatocytes is sensitive to the thiol redox 
status of the cell (Tirmenstein MA, 2000).  
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MMP activity in wound healing is vital for most of the physiological 
processes, for e.g. epithelialisation, debridement, infiltration of 
inflammatory and parenchymal cells (Chia Soon, 2000). The above-
mentioned processes occur mainly during the phase of inflammation (up-
to 3 days) and phase of ECM deposition and re-epithelialisation (up-to 10 
days). The activity of MMP is not affected in the initial phase. This 
indicates that GSNO does not affect the vital physiological process i.e. 
MMP activity, which in turn regulates dissolution of clot, debridement 
and keratinocyte migration. Though it has been found that GSNO 
inhibits MMP activity in platelets and in turn inhibits platelet 
aggregation the effect is not to such an extent to affect healing. 
Debridement, inflammation and epithelialisation were all maintained as 
it was observed that the wounds healed without any delay. GSH inhibited 
the activity of MMP and this was similar to previous observations 
(Gundumi Aravinda Upadhya, 2000). Suresh C. Tyagi et al (1996) have 
also demonstrated that reduced GSH reduces the transcription of MMP 
expression and fibroblast proliferation in normal cardiac fibroblasts.  
This is the first report describing the effects of nitrosothiols on wound 
collagen and MMP activity. In our study we have observed an increase in 
the collagen content without any interference of MMP activity. 
Alteration of this vital process would result in aberrant healing. Any 
wound enhancing agent necessarily has to have no effect on these 
enzymes. Certain reports regarding inhibition of MMP activity by NO 
have been carried out in an in-vitro set-up (Paul Jurasz, 2001). The 
MMP inhibitory effect in an in vivo model may not be as profound as in 
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an in vitro model, as the NO donor compounds undergo various 
intermediary metabolisms which require the presence certain other cells. 
Our report suggests that enhanced collagen deposition, uninhibited 
MMP activity and thiol status favor enhanced wound healing. The 
mechanisms of MMP regulation by various RSNOs are yet to be studied 
in detail. The facilitatory and the regulatory effects of GSNO on wound 
healing following its biotransformation in the wound environment may 
provide possible targets for further research in the enhancement of 
wound healing 
5.4 General discussion 
Nitric oxide produced in the cells may function in non-specific host 
defense during wound healing. This presumably occurs because nitric 
oxide either alone or in combination with other reactive oxygen species is 
cytotoxic (Moncada 1991). Nitric oxide is also important in regulating 
cell proliferation (keratinocyte and fibroblast) in the wound 
environment. The cytotoxic effects of NO are either due to complex 
formation with the iron-sulphur moiety of proteins, resulting in 
inhibition of the proteins or activation of metabolic pathways. The 
binding of nitric oxide to the heme-containing guanylate cyclase activates 
this enzyme resulting in increased intracellular levels of cGMP an 
important regulator of cell growth and differentiation (Moncada 1991). 
Nitric oxide also inhibits ribonucleotide reductase (Kwon N.S 1990) as 
well as mitochondrial respiration and DNA synthesis, events that control 
cellular proliferation and are important in non-specific host defense. The 
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effect of NO on cells is considered biphasic, as lower concentrations are 
protective against oxidative killing and higher doses enhance oxidative 
killing (Mahesh.S.Joshi et al, 1999). The clear variation of responses of 
GSNO and SNAP can be understood based on the above observations 
that SNAP caused an increased oxidative damage at higher concentration 
by depleting intracellular GSH.  The beneficial effect of GSNO can be 
explained by its breakdown into GSH and NO, thus providing an 
efficient and well-balanced antioxidant and a signal transduction 
molecule. Therefore it is important to modulate/ control this equilibrium 
so as to achieve appropriate wound healing. These redox mechanisms are 
well known to regulate inflammatory responses in various other tissues 
and as well as in many dermatidis. We therefore hypothesized that 
agents, which affect the equilibrium, can also alter wound healing. 
Because of the differences in investigative conditions e.g. choice of 
experimental animal, mode of administration of the drugs and healing 
time studied, it is difficult to compare the results. In conclusion these 
results demonstrate that the administration of nitrosoglutathione has 
beneficial effects on wound healing compared to SNAP, which is a NO 
donor of the same group. Administration of glutathione alone does not 
enhance healing. The net biological effects of GSNO may therefore 
depend upon the complex interactions of various resident and immune 



















6.1     Conclusions 
 
 
Normal wounds heal completely in a period of 12-14 days. The Rate of wound 
healing calculated by measuring length and breadth of clearly defined wounds with 
proper edges is a repeatable and comparable method. This is limited to 
experimental models, as in clinical situations the wound volume varies and the 
borders are not clear-cut. Anyhow this method can be adopted in examining the 
effects of pharmacological agents in an animal model. In this study administration 
of nitrosoglutathione increased the rate of wound healing. Aminoguanidine, an 
iNOS inhibitor did not affect wound healing either positively or negatively. 
To compare the effects of GSNO on wound healing, animals were treated with GSH 
and another NO donor belonging to the same class of compounds. The effect on 
wound healing was quantified by measuring collagen content (hydroxyproline), 
material property (load & stiffness), gelatinase activity and scar glutathione 
concentrations. Our results revealed that neither SNAP (a NO donor) nor GSH (an 
antioxidant) showed any significant improvement of quantitative parameters of 
wound healing. GSNO improved strength and collagen content of the scars. SNAP 
& GSH significantly decreased the strength, collagen content and MMP activity in 
the scars. The plasma nitrite and nitrate increased, following GSNO & SNAP 
treatment. In the GSNO group plasma nitrite increased only till the 3rd hour 
following which it returned to normal. SNAP showed increased plasma nitrite for 5 
hours post-injection. SNAP significantly decreased the wound GSH content 
beginning from the 3rd post-operative day, lasting till the 10th day. AG mainly had 
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the following effects: 1) rate of wound contraction was not altered 2) lowered 
collagen content 3) increased gelatinase activity by the third post-wounding day and 
4) scar nitrite and nitrate were significantly lowered. 
The effects of injection of NO donors and inhibitors on the peritoneum were 
monitored by the expression of immune cell markers. MHC class I had no 
difference. SNAP increased expression of class II markers. ICAM was found to be 
lower in the GSNO, SNAP and AG treated groups. The variation in the expression 
of peritoneal cells markers is not significant as to prove that i.p. administration of 
these drugs did not alter immunity. The NOS isoenzyme localization by 
immunohistochemical methods revealed no significant change in the treatment 
groups. 
Thus, our study shows that GSNO improves wound healing by improving collagen 
content and material property of the scar. This can be hypothesized due to the 
combined effects of NO and GSH component of this compound. The various 
mechanisms, which are regulated by accumulation of intracellular GSNO, its 






6.2 Future directions 
NO is a key regulator of many biochemical pathways which regulate tissue 
responses to injury. It is of interest to further look into the effect of nitric oxide in 
the following areas of wound healing and tissue repair. 
1. Elucidate novel mechanisms by which NO and GSH influence the response of 
a cell to injury. In a tissue such as skin, the effects of NO and GSH 
interaction are complex as there are numerous immune cells along with 
resident parenchymal cells. 
2. The start signals for cell proliferation and differentiation are to be identified 
and the pharmacological manipulation of this process holds a high potential 
for drug discovery. 
3. The clinical applications of drugs that alter the redox pathway are numerous. 
Clinical trials on such drugs in ischaemic ulcers, non-healing wounds and 
pressure sores need to be conducted. NO donors with anti-microbial and 
vasodilatory effects are potential candidates in this aspect. 
4. It would be interesting to identify an ideal NO donor, which has prolonged 
half-life and augments repair by increasing the keratinocyte proliferation 
without inhibiting the inflammatory pathways such as activation of NF-κB.  
5. The efficacy of topical nitric oxide donors in conditions such as diabetic 
ulcers, infected wounds and in ischaemic ulcers needs to be studied.  
Because of their wide range of effects, RSNOs have great potential as therapeutic 
agents. They may be particularly useful alternatives to organic nitrates, as they do 
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not lead to the development of tolerance. However, interactions with copper, thiols, 
ascorbic acid and other reducing agents may influence their stability and ability to 
act as useful therapeutic agents. As yet RSNOs have only been used intravenously in 
animal studies and small clinical trials. Further study of their pharmacology is 
warranted, particularly to determine whether oral preparations might be available 
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CONTENTS OF THE KIT
Number Item Quantity
1 MES Buffer (2X) 1 vial
2 GSSG Standard 1 vial
3 Cofactor Mixture 1 vial
4 Enzyme Mixture 1 vial
5 DTNB 4 vials
6 96 Well Plate 1 plate
7 Plate Cover 1 cover
If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or 
(734) 971-3335. We cannot accept any returns without prior authorization.
2PRECAUTIONS
• Please read these instructions carefully before beginning this assay.
• For research use only. Not for human or diagnostic use.
WARRANTY AND LIMITATION OF REMEDY
Cayman Chemical Company makes no warranty of any kind, expressed or implied, including, but not limited to, the warranties of fitness
for a particular purpose and merchantability, which extends beyond the description of the chemicals on the face hereof, except that the 
material will meet our specifications at the time of delivery. Buyer’s exclusive remedy and Cayman Chemical Company’s sole liability 
hereunder shall be limited to refund of the purchase price of, or at Cayman Chemical Company’s option, the replacement of, all material
that does not meet our specifications. Cayman Chemical Company shall not be liable otherwise or for incidental or consequential damages,
including, but not limited to, the costs of handling. Said refund or replacement is conditioned on Buyer giving written notice to Cayman
Chemical Company within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within said
thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.
IF YOU HAVE PROBLEMS
Our technical support staff may be reached by phone (800-364-9897, 734-971-3335), fax (734-971-3640), or E-Mail 
(techserv@caymanchem.com) Monday through Friday 8:00 AM to 6:00 PM EST. In order for our staff to assist you quickly and 
efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).
STORAGE AND STABILITY
This kit will perform as specified if stored at 4°C and used before the expiration date indicated on the outside of the box.
ADDITIONAL ITEMS REQUIRED
1. A plate reader with a 414 or 405 nm filter.
2. An adjustable pipettor, repeat pipettor, and an eight channel pipettor (optional).
3. A source of pure water. Glass distilled water or HPLC-grade water is acceptable.
4. Metaphosphoric acid and triethanolamine (described on page 6).
5. 2-vinylpyridine (optional, described on page 6).
ABOUT THIS ASSAY
Glutathione (GSH) is a tripeptide (g -glutamylcysteinylglycine) widely distributed in both plants and animals.1,2 GSH serves as a 
nucleophilic co-substrate to glutathione transferases in the detoxification of xenobiotics and is an essential electron donor to glutathione 
peroxidases in the reduction of hydroperoxides.2,3 GSH is also involved in amino acid transport and maintenance of protein sulfhydryl
reduction status.4,5 Concentration of GSH ranges from a few micromolar in plasma to several millimolar in tissues such as liver.6,7
Cayman’s GSH assay kit utilizes a carefully optimized enzymatic recycling method, using glutathione reductase, for the quantification of
GSH (see Figure 1, page 3).8-10 The sulfhydryl group of GSH reacts with DTNB (5,5’-dithiobis-2-nitrobenzoic acid, Ellman’s reagent) and
produces a yellow colored 5-thio-2-nitrobenzoic acid (TNB). The mixed disulfide, GSTNB (between GSH and TNB) that is 
concomitantly produced, is reduced by glutathione reductase to recycle the GSH and produce more TNB. The rate of TNB production is
directly proportional to this recycling reaction which is in turn directly proportional to the concentration of GSH in the sample.
Measurement of the absorbance of TNB at 405 or 414 nm provides an accurate estimation of GSH in the sample.
3GSH is easily oxidized to the disulfide dimer GSSG. GSSG is produced during the reduction of hydroperoxides by glutathione peroxidase.
GSSG is reduced to GSH by glutathione reductase and it is the reduced form that exists mainly in biological systems. Because of the use of
glutathione reductase in the Cayman GSH assay kit, both GSH and GSSG are measured and the assay reflects total glutathione. The kit can
also be used to measure only GSSG by following the protocol given on page 6. GSH measurement can be done in plasma, serum, 
erythrocyte lysates, tissue samples, and cultured cells using this kit. However, plasma and serum samples will have to be concentrated before
assaying, and nearly all samples will require deproteination (see page 6 for more details).
Figure 1.  GSH Recycling
SENSITIVITY
Under the standardized conditions of the assay described in this booklet, the dynamic range of the kit is 0 - 16 µM GSH (or 0 - 8 µM
GSSG).
PRE-ASSAY PREPARATION
Reconstitution of the Reagents
Some of the kit components are in lyophilized form and need to be reconstituted prior to use. Follow the directions carefully to ensure 
proper volumes of water or Assay Buffer are used to reconstitute the vial components.
1. MES Buffer (2X) - (vial #1)
The buffer consists of 0.4 M 2-(N-morpholino)ethanesulphonic acid, 0.1 M phosphate, and 2 mM EDTA, pH 6.0. Dilute the buffer
with equal volume of water before use. Hereafter, MES Buffer refers to this diluted buffer.
2. GSSG Standard - (vial #2)
The vial contains 25 µM GSSG in MES buffer. This standard is ready to use as supplied. NOTE: GSSG is provided as a standard instead
of GSH. Under the assay conditions, GSSG is immediately reduced to GSH thereby providing the necessary standard. The standard is
stable for at least 6 months if stored as supplied at 0 - 4°C.
3. Cofactor Mixture - (vial #3)
The vial contains a lyophilized powder of NADP+ and glucose-6-phosphate. Reconstitute the contents of the vial with 0.5 ml of water
and mix well. The reconstituted reagent will be stable for 2 weeks if stored at 0 - 4 °C.
4. Enzyme Mixture - (vial #4)
The vial contains glutathione reductase and glucose-6-phosphate dehydrogenase in 0.2 ml buffer. Carefully open the vial without
spilling any liquid from the cap. Add 2 ml of diluted MES Buffer to the vial, replace the cap, and mix well. The reconstituted Enzyme
Mixture will be stable for 2 weeks if stored at 0 - 4 °C.
5. DTNB - (vial #5)*
Each vial contains a lyophilized powder of DTNB (5,5’-dithiobis-2-nitrobenzoic acid, Ellman’s reagent). Reconstitute the contents of
the vial with 0.5 ml of water and mix well. The reconstituted reagent must be used within 10 minutes.
*Reconstitution of this reagent should be done just prior to its addition to the Assay Cocktail described on page 7. Four vials of this reagent











• When pipetting the Assay Cocktail (see below), we recommend an eight channel pipet be used to
save time and maintain more precise times of incubation.
• Before pipetting each reagent, equilibrate the pipet tip (i.e., fill the tip and expel the contents 
several times)
• Do not expose the pipet tip to the reagent(s) already in the well.
SAMPLE PREPARATION
CAUTION: Thiol compounds such as mercaptoethanol, dithiothreitol, etc., or thiol alkylating agents such as N-ethylmaleimide should not
be added to the samples at any stage of sample collection or preparation. If the samples contain any of these compounds they are unsuitable
for GSH quantification.
Tissue Homogenate
1. Prior to dissection, perfuse tissue with a PBS (phosphate buffered saline) solution, pH 7.4, containing 0.16 mg/ml heparin to remove
any red blood cells and clots.
2. Homogenize the tissue in 5-10 ml of cold buffer (i.e., 50 mM MES or phosphate, pH 6-7, containing 1 mM EDTA) per gram tissue.
3. Centrifuge at 10,000 x g for 15 minutes at 4°C.
4. Remove the supernatant and store on ice.
5. The supernatant will have to be deproteinated before assaying (see page 6). If not assaying on the same day, the sample will still have
to be deproteinated, and then stored at -20°C. The sample will be stable for at least six months.
Plate configuration
There is no specific pattern for using the wells on the plate. A typical layout of standards and samples to be measured in triplicate is given
below (see Figure 2). We suggest you record the contents of each well on the template sheet provided (see page 11).
Figure 2.  Sample Plate Format
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1. Collect cells by centrifugation (i.e., 1,000-2,000 x g for 10 minutes at 4°C). For adherent cells, do not harvest using proteolytic enzymes;
rather use a rubber policeman.
2. The cell pellet can be homogenized or sonicated in 1-2 ml of cold buffer (i.e., 50 mM MES or phosphate, pH 6-7, containing 1 mM
EDTA).
3. Centrifuge at 10,000 x g for 15 minutes at 4°C.
4. Remove the supernatant and store on ice.
5. The supernatant will have to be deproteinated before assaying (see page 6). If not assaying on the same day, the sample will still have
to be deproteinated, and then stored at -20°C. The sample will be stable for at least six months.
Plasma and Erythrocyte lysate
1. Collect blood using an anticoagulant such as heparin, citrate, or EDTA.
2. Centrifuge the blood at 700-1,000 x g for 10 minutes at 4°C. Pipet off the top yellow plasma layer without disturbing the white buffy
layer. Store plasma on ice. 
3. Remove the white buffy layer (leukocytes) and discard.
4. Lyse the erythrocytes (red blood cells) in 4 times its volume of ice-cold HPLC-grade water.
5. Centrifuge at 10,000 x g for 15 minutes at 4°C.
6. Collect the supernatant (erythrocyte lysate) and store on ice.
7. The plasma and erythrocyte lysate will have to be deproteinated before assaying (see page 6). If not assaying on the same day, the 
samples will still have to be deproteinated, and then stored at -20°C. The samples will be stable for at least six months. NOTE: Plasma 
samples contain glutathione levels below the detection limit of the assay and thus can not be measured directly. Before assaying, add
TEAM reagent to the deproteinated plasma sample (see page 6), concentrate by lyophilization, and then reconstitute the sample with
MES Buffer to one third of its original volume. You will only be able to determine the total GSH content. We do not guarantee the
accuracy of the GSSG content due to the many manipulations that the plasma sample has endured.
Serum
1. Collect blood without using an anticoagulant such as heparin, citrate, or EDTA. Allow blood to clot for 30 minutes at 25°C.
2. Centrifuge the blood at 2,000 x g for 15 minutes at 4°C. Pipet off the top yellow serum layer without disturbing the white buffy layer.
Store serum on ice.
3. The serum will have to be deproteinated before assaying (see page 6). If not assaying on the same day, the sample will still have to be
deproteinated, and then stored at -20°C. The sample will be stable for at least six months. NOTE: Serum samples contain glutathione
levels below the detection limit of the assay and thus can not be measured directly. Before assaying, add TEAM reagent to the 
deproteinated serum sample (see page 6), concentrate by lyophilization, and then reconstitute the sample with MES Buffer to one third
of its original volume. You will only be able to determine the total GSH content. We do not guarantee the accuracy of the GSSG 
content due to the many manipulations that the serum sample has endured.
6Recommended procedure for deproteination of samples:
Almost all biological samples used for GSH measurement contain large amounts of proteins, e.g., erythrocyte lysate, tissue homogenates,
etc. It is necessary to remove as much protein as possible from the sample to avoid interferences due to particulates and sulfhydryl groups
on proteins in the assay. Samples that are low in protein (<1 mg/ml) and are devoid of particulates can be assayed directly.
1. MPA reagent: Dissolve 5 g of metaphosphoric acid (Aldrich, Cat# 43157-5 or 23927-5) in 50 ml water. The MPA solution is stable for
4 hours at 25°C.
2. Add an equal volume of the MPA reagent to the sample and mix it on a vortex mixture. Allow the mixture to stand at room 
temperature for 5 minutes and centrifuge at >2000 g for at least 2 minutes (a microfuge will be sufficient for the centrifugation).
Carefully collect the supernatant without disturbing the precipitate. The supernatant can be stored at this stage for long periods of time
(up to 6 months) at -20°C without any degradation of GSH or GSSG. Do not add TEAM reagent until you are ready to assay the 
sample.
3. TEAM reagent: Prepare a 4 M solution of triethanolamine (Aldrich, Cat# T5830-0) in water by mixing 531 µl of triethanolamine with
469 µl of water. The TEAM solution is stable for 4 hours at 25°C.
4. Add 50 µl of TEAM reagent per ml of the supernatant and vortex immediately. The TEAM reagent will increase the pH of the sample.
The sample is ready for assay of total GSH (i.e., both oxidized and reduced). Any necessary dilutions of the sample should be done at
this stage with MES Buffer.
Sample preparation for exclusive measurement of GSSG:
Quantification of GSSG, exclusive of GSH, is accomplished by first derivatizing GSH with 2-vinylpyridine.11 This can be achieved as 
follows:
1. Prepare a 1 M solution of 2-vinylpyridine (Aldrich, Cat# 13229-2) in ethanol by mixing 108 µl of 2-vinylpyridine and 892 µl of
ethanol.
2. Add 10 µl of the 2-vinylpyridine solution per ml of sample from step 4 above. Mix well on a vortex mixer and incubate at room 
temperature for about 60 minutes and assay the sample.* This procedure can derivatize up to 1 mM GSH. More concentrated samples
should be diluted with MES Buffer before derivatization.
*2-Vinylpyridine inhibits color development in the assay to some extent. Hence, it is essential to prepare the standards also the same way by
adding 2-vinylpyridine (i.e., add 5 µl of 2-vinylpyridine solution per tube described below) and incubating to the same length of time
as the sample.
PERFORMING THE ASSAY
• All reagents must be equilibrated to room temperature before beginning the assay.
• The volume of sample and standards added to the wells is 50 µl and the final volume of the assay is 200 µl in all the wells.
• It is not necessary to use all the wells on the plate at one time. However, a standard curve must be run simultaneously with each set
of samples.
• Add TEAM reagent to the deproteinated samples (see deproteination procedure, page 6).
• Use diluted MES Buffer in the assay.
• If the expected concentration of GSH in the sample is not known or if it is expected to be beyond the range of the standard curve, it
is prudent to assay the sample at several dilutions.
• It is recommended that the samples and standards be assayed at least in duplicate.
• Prepare the Assay Cocktail (see below) just before its addition to the wells.
• Addition of the Assay Cocktail (see below) to the wells must be done as quickly as possible. The time difference in addition between
the first well to the last should not be more than 2 minutes. 
1. Preparation of the standards: Take eight clean test tubes and mark them A-H. Aliquot the GSSG standard (vial #2) and MES Buffer to
each tube as described in Table 1.
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Tube GSSG Standard (µl) MES Buffer (µl) Final Concentration Equivalent
(µM GSSG) Total GSH (µM)*
A 0 500 0 0
B 5 495 0.25 0.5
C 10 490 0.5 1.0
D 20 480 1.0 2.0
E 40 460 2.0 4.0
F 80 420 4.0 8.0
G 120 380 6.0 12.0
H 160 340 8.0 16.0
*Under the assay conditions GSSG is reduced to produce 2 mole equivalents of GSH.
Table 1
2. Add 50 µl of standard (tubes A - H) per well in the designated wells on the plate (see suggested plate configuration, Figure 2, page 4).
3. Add 50 µl of sample to each of the sample wells.
4. Cover the plate with the plate cover provided.
5. Prepare the Assay Cocktail by mixing the following reagents in a 20 ml vial: MES Buffer (11.25 ml), reconstituted Cofactor Mixture
(0.45 ml), reconstituted Enzyme Mixture (2.1 ml), water (2.3 ml), and reconstituted DTNB (0.45 ml).
NOTE: The volumes of reagents given are for the use of the entire plate. Adjust the volumes of the reagents accordingly if only a part of the
plate is used.
Prepare fresh Assay Cocktail and run a standard curve each time the assay is performed.
Use the Assay Cocktail within 10 minutes of preparation.
6. Remove the plate cover and add 150 µl of the freshly prepared Assay Cocktail to each of the wells containing standards and samples
using a multichannel pipet. Replace the plate cover and incubate the plate in the dark on an orbital shaker.
7. Measure the absorbance in the wells at 405 or 414 nm using a plate reader at 5 minutes intervals for 30 minutes (a total of 
6 measurements). (NOTE: If only the end point method of calculation (see below) is used, one measurement at 25 minutes is enough.)
Expected absorbance of the lowest standard (standard A) at 405 nm is 0.15 - 0.25 AU and that of the highest standard (standard H) is
0.6 - 0.8 AU in 30 minutes.
CALCULATING THE RESULTS
GSH concentration of the samples can be determined either by the End Point Method or the Kinetic Method. The End Point Method is
adequate for most purposes. However, if the levels of cysteine or other thiols in the samples are expected to be significant compared to GSH,
the Kinetic Method should be used.
End Point Method
1. Calculate the average absorbance from the 25 minutes measurement for each standard and sample.
2. Subtract the absorbance value of the standard A from itself and all other values (both standards and samples). This is the corrected
absorbance.
3. Plot the corrected absorbance values (from step 2 above) of each standard as a function of the concentration of GSSG or Total GSH of
Table 1 (see Figure 3, page 8).
Figure 3.  Plot of corrected Absorbance at 25 minutes vs. GSH concentration (µM)
4. Calculate the values of GSSG or Total GSH for each sample from the standard curve.
[Total GSH] or [GSSG] = {(absorbance at 405 or 414 nm) - (y-intercept)}/slope x 2* x sample dilution
*NOTE: If your sample required deproteination, multiply by “2” to account for the addition of MPA Reagent.
Kinetic Method
1. Plot the average absorbance values of each standard and sample as a function of time and determine the slope for each curve 
(see Figure 4). This is called i-slope.
Figure 4.  Plot of Absorbance vs. Time for each standard
2. Plot the i-slopes of each standard as a function of the concentration of GSSG or total GSH of Table 1 (see Figure 5, page 9). The slope















































y = 0.0107 + 0.0328x   r2 = 0.999
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Figure 5.  Plot of Slope vs. GSSG concentration
3. Calculate the values of GSSG or total GSH for each sample from their respective slopes using the slope versus GSSG or GSH standard
curve.
[Total GSH] or [GSSG] = {(i-slope for the sample) - (y-intercept)}/f-slope x 2* x sample dilution
*NOTE: If your sample required deproteination, multiply by “2” to account for the addition of MPA Reagent.
INTERFERENCES
Added thiols such as mercaptoethanol, dithiothreitol, etc., and high levels of cysteine will consume all the DTNB and cause severe 
interference in the estimation of GSH. Thiol alkylating agents such as N-ethylmaleimide will inhibit glutathione reductase thereby 
rendering the assay ineffective.
TROUBLESHOOTING
Problem: Erratic values; dispersion of duplicates.
Cause: Poor pipetting/technique. -or- Bubble(s) in the well.
Problem: No color development.
Cause: One or more of the constituents of Assay Cocktail missing -or- Standards not added to the wells.
Solution: Make sure to add all components to the Assay Cocktail and the wells.
Problem: Non-linear standard curve.
Cause: Absorbance values too high (>1.2) at high GSH concentrations.
Solution: Use the absorbance measured at lower time points. Ideally, the highest point on the standard curve should have an absorbance
value less than 1.2 AU.
Problem: No color in the sample above the background.
Cause: Concentration of GSH in the sample is too low (<0.25 µM).
Solution: Concentrate the sample by lyophilization and reconstitute in a smaller volume of MES Buffer than the original volume of the
sample. Concentration should be performed after deproteination of the sample.
Problem: Absorbance value of the sample higher than the highest point of the standard curve.
Cause: Sample is too concentrated and/or high concentration of other thiols.
Solution: Dilute the sample and reassay. Analyze the data using Kinetic Method. If the absorbance value falls within the range of any of













y = 0.0032 + 0.0020x   r2 = 0.997
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RELATED PRODUCTS
4-hydroxy Hexenal - Cat. No. 32060 • 4-hydroxy Nonenal - Cat. No. 32100 • 8-Isoprostane EIA Kit - Cat. No. 516351 • Glutathione
Peroxidase Assay Kit - Cat. No. 703102 • Glutathione Reductase Assay Kit - Cat. No. 703202 • Glutathione S-Transferase Assay Kit - Cat.
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